

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number
WO 03/054228 A2

- (51) International Patent Classification⁷: C12Q 1/68 (74) Agents: GINZEL, Christian et al.: c/o Zimmermann & Partner, Postfach 330 920, 80069 Munich (DE).
- (21) International Application Number: PCT/EP02/14578
- (22) International Filing Date:
19 December 2002 (19.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/341,757 21 December 2001 (21.12.2001) US
- (71) Applicant (for all designated States except US): AXXIMA PHARMACEUTICALS AG [DE/DE]; Am Klopferspitz 19, 82152 Martinsried (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SALASSIDIS, Konstadinos [GR/DE]; Hauptstrasse 14c, 85386 Eching (DE). SCHUBART, Daniel [DE/DE]; Avenue Charles de Gaulle 1c, 13469 Berlin (DE). GUTBROD, Heidrun [DE/DE]; Weberhofstrasse 8, 82166 Graefelfing (DE). MUELLER, Stefan [DE/DE]; Thalkirchnerstrasse 184, 81371 Munich (DE). KRAETZER, Friedrich [DE/DE]; Geisenbrunnerstrasse 51, 81475 Munich (DE). OBERT, Sabine [DE/DE]; Bellinzonastrasse 17, 81475 Munich (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN CELLULAR PROTEIN KINASES, METALLOPROTEASES AND PHOSPHATASES AS TARGETS FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS

(57) Abstract: The present invention relates to human cellular protein kinases, metalloproteases and one phosphatase: beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1 (NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649) as potential targets for medical intervention against Hepatitis C virus (HCV) infections. The present invention relates also to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections, a method for detecting Hepatitis C virus infections in an individual or in cells. Mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production and/or replication wherein said antibodies may be used. Finally the present invention relates to a solid support useful for detecting Hepatitis C virus infections or for screening compounds useful for prophylaxis and/or treatment of HCV infections.

WO 03/054228 A2

**Human cellular protein kinases, metalloproteases and phosphatases
as targets for medical intervention against Hepatitis C virus infections**

5

Specification

The present invention relates to the human cellular protein kinases, metalloproteases and phosphatases:

- 10 1. beta-adrenergic receptor kinase 1 (NM_001619, X61157, ADRBK1, GRK2, BARK1);
2. Mitogen activated protein kinase activated protein kinase 5 (AF032437, MAPKAPK5, PRAK,);
3. Insulin-stimulated protein kinase 1 (U08316, ribosomal protein S6 kinase 3
15 90K);
4. Discoidin domain receptor family, member 1 (NM_013994, DDR1, TRK E, NEP, CAK, X74979);
5. Protein Kinase C, mu (X75756, PKC-mu);
6. Protein Kinase C, theta (L01087, PKC-theta);
- 20 7. AMP-activated protein kinase beta 2 subunit (AJ 224538, AMPK beta 2);
8. JNK2 (U09759, L31951);
9. Human p21-activated protein kinase 2 (U24153, PAK2);
10. cyclin-dependent kinase 4 (U37022, cdk4);
11. MEK5 (U25265, Mitogen-activated protein kinase kinase 5);
- 25 12. MKP-L or DUSP14, formally also named as MKP-1 like tyrosine phosphatase (NM_007026, AF038844);
13. ADAM22 (NM_016351, AF155382; a disintegrin and metalloproteinase domain 22);
14. ADAM17 (U92649, XM_002270; a disintegrin and metalloproteinase domain
30 17);

as potential targets for medical intervention against Hepatitis C virus (HCV) infections. Furthermore, the present invention relates to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C

virus infections and a method for detecting Hepatitis C virus infections in an individual or in cells. Also mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production wherein said
5 antibodies may be used. Finally the present invention relates to a solid support useful for detecting Hepatitis C virus infections or for screening compounds useful for prophylaxis and/or treatment of HCV infections.

10 **Background of the invention**

Hepatitis C Virus (HCV) infection is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma. The WHO estimates that approximately 3% of the world population, or 170 million people, have been infected with the Hepatitis C Virus. In the U.S., an estimated 3.9 million Americans have been infected (CDC
15 fact sheet Sept. 00). Over 80% of HCV-infected individuals develop chronic hepatitis, which is associated with disease states ranging from asymptomatic carrier states to repeated inflammation of the liver and serious chronic liver disease. Over the course of 20 years, more than 20% of chronic HCV-patients are expected to be at risk to develop cirrhosis or progress to hepatocellular
20 carcinoma. Liver failure from chronic hepatitis C is the leading indicator for liver transplantation. Excluding transplantation, the CDC estimates that medical and work-loss cost for HCV annually are around \$600 million. HCV is transmitted primarily by blood and blood products. Due to routine screening of the blood supplies from mid-1992, new transfusion-related cases are exceedingly rare and
25 have been surpassed by injection drug use as the highest risk factor for acquiring the virus. There is also a sexual, however inefficient, route of transmission, and a 6% rate of transmission from infected mothers to their children, which is higher in case of HIV coinfection. In a certain percentage of infections, the mode of transmission remains unknown. In spite of the significant decline in incidence in
30 the 1990's, the number of deaths (estimated deaths annually at the moment: 8000 to 10,000 in U.S.) and severe disease due to HCV is anticipated to triple in the next 10 to 20 years. (Sources: CDC fact sheet (accessed 12/12/00); Houghton M. Hepatitis C Viruses. In BN Fields, DM Knipe, PM Howley (ed.) Fields Virology.

1996. Lippencott-Raven Pub., Philadelphia; Rosen HR and Gretch DR, Molecular Medicine Today Vol5, 393, Sept. 99; Science 285, 26, July 99: News Focus: The scientific challenge of Hepatitis C; Wong JB et al, Am J Public Health, 90, 1562, Oct 2000: Estimating future hepatitis C morbidity, mortality, and costs in the United States).

According to the Consensus Statement from the EASL (European Association for the Study of the Liver) International Consensus Conference on Hepatitis C (February 26-28, 1999, Paris, France), combination therapy of alpha interferon and ribavirin is the recommended treatment for naive patients. Monotherapy with interferon has also been approved by the FDA, but the sustained response rate (HCV RNA remains undetectable in the serum for more than 6 months after end of therapy) is only 15 to 20%, in contrast to 35 to 45% with combination therapy. Interferons (Intron A, Schering-Plough; Roferon A, Hoffmann-LaRoche; Wellferon, Glaxo Wellcome; Infergen, Amgen) are injected subcutaneously three times a week, ribavirin (Rebetol, Schering-Plough) is an oral drug given twice a day. Recommended treatment duration is 6 to 12 months, depending on HCV genotype. Experimental forms of slow-release pegylated interferons (Pegasys, Hoffmann-LaRoche; PEG-Intron, Schering-Plough) have shown improvements in response rates (42 to 82% in combination with ribavirin) and application (once-weekly injection) in recent clinical studies (Hepatology32:4, Pt 2 of 2. Oct 2000; NEJM 343, 1673. Dec 00; NEJM 343, 1666. Dec 00). Common side effects of interferon therapy include: fatigue, muscle aches, head aches, nausea, fever, weight loss, irritability, depression, bone marrow suppression, reversible hair loss. The most common side effects of ribavirin are anemia, fatigue and irritability, itching, skin rash, nasal stuffiness, sinusitis, cough. More serious side effects of mono-and combination therapy occur in less than two percent of patients (NIDDK information: Chronic Hepatitis C: Current Disease Management. accessed 09.12.99). Some of the contraindications to interferon are psychosis or severe depression; neutropenia and/or thrombocytopenia; organ transplantation except liver; symptomatic heart disease; decompensated cirrhosis; uncontrolled seizures. Contraindications to ribavirin are end-stage renal failure; anemia;

hemoglobinopathies; severe heart disease; pregnancy; no reliable method of contraception (consensus statement EASL).

Experimental treatments that are not new forms of interferon are Maxamine
5 (histamine dihydrochloride, Maxim Pharmaceuticals), which will be combined with
Interferon in phase III studies, VX-497 (Vertex Pharmaceuticals), an IMP
dehydrogenase inhibitor, as a less toxic ribavirin substitute in phase II, and
amantadine (Endo Labs), an approved influenza drug, as the third component in
triple therapy (phase II). Inhibitors for HCV enzymes such as protease inhibitors,
10 RNA polymerase inhibitors, helicase inhibitors as well as ribozymes and antisense
RNAs are under preclinical development (Boehringer Ingelheim, Ribozyme
Pharmaceuticals, Vertex Pharmaceuticals, Schering-Plough, Hoffmann-LaRoche,
Immusol, Merck etc.). No vaccine is available for prevention or therapeutic use,
but several companies are trying to develop conventional or DNA vaccines or
15 immunostimulatory agents (e.g. Chiron, Merck/Vical, Epimmune, NABI,
Innogenetics).

In summary, the available treatment for chronic Hepatitis C is expensive, effective
only in a certain percentage of patients and adverse side effects are not
20 uncommon.

Description of the invention

Recent research has revealed how cells communicate with each other to
25 coordinate the growth and maintenance of the multitude of tissues within the
human body. A key element of this communication network is the transmission of
a signal from the exterior of a cell to its nucleus, which results in the activation or
suppression of specific genes. This process is called signal transduction.

30 An integral part of signal transduction is the interaction of ligands, their receptors
and intracellular signal transduction molecules. Ligands are messengers that bind
to specific receptors on the surface of target cells. As a result of the binding, the
receptors trigger the activation of a cascade of downstream signaling molecules,

thereby transmitting the message from the exterior of the cell to its nucleus. When the message reaches the nucleus, it initiates the modulation of specific genes, resulting in the production of RNA and finally proteins that carry out a specific biological function. Disturbed activity of signal transduction molecules
5 may lead to the malfunctioning of cells and disease processes. Specifically, interaction of HCV with host cells is necessary for the virus to replicate.

The present invention is based upon the discovery of a group of human cellular protein kinases, metalloproteases and one phosphatase which are specifically up-
10 or downregulated as a result of HCV replication in HCV infected host cells. The antiviral therapeutic research approach described herein focuses on discovering the cellular signal transduction pathways involved in viral infections. Identification of the signal transduction molecules, key to viral infection, provides for, among other things, novel diagnostic methods, for example, assays and compositions
15 useful therefore, novel targets for antiviral therapeutics, a novel class of antiviral therapeutics, and new screening methods (e.g. assays) and materials to discover new antiviral agents.

This approach led to the development of a novel microarray platform technology,
20 wherein a microarray of more than 900 signal transduction cDNAs was developed. This unique microarray technology was used to identify changes in RNA expression patterns (e.g. upregulation or downregulation) as a result of HCV infected host cells. Differential display techniques were used to pinpoint those signal transduction molecules useful as targets for drug intervention. Effective
25 manipulation of these virally-controlled intracellular signal transduction pathways can alter (slow or stop altogether) the course of viral growth.

It is object of the present invention to provide novel targets for medical intervention, prophylaxis and/or treatment of Hepatitis C virus infections in
30 mammals, including humans, and cells together with methods for detecting HCV infections in individuals and cells and methods for detecting compounds useful for prophylaxis and/or treatment of HCV infections. The object of the present

invention is solved by the teaching of the independent claims. Further preferred embodiments are disclosed in the dependent claims.

It is now revealed for the first time that the human cellular proteins

- 5 beta-adrenergic receptor kinase 1 (gene accession number NM_001619, other names: X61157, ADRBK1, GRK2, BARK1),
Mitogen activated protein kinase activated protein kinase 5 (also known as: AF032437, MAPKAPK5, or PRAK),
Insulin-stimulated protein kinase 1 (also known as: U08316, ribosomal protein S6
10 kinase 3 90K),
Discoidin domain receptor family, member 1 (gene accession number NM_013994, other names: X74979, DDR1, TRK E, NEP, or CAK),
Protein Kinase C, mu (also known as: X75756 or PKC-mu),
Protein Kinase C, theta (also known as: L01087 or PKC-theta),
15 AMP-activated protein kinase beta 2 subunit (also known as: AJ 224538 or AMPK beta 2),
JNK2 (also known as: U09759 or L31951),
Human p21-activated protein kinase 2 (also known as: U24153 or PAK2),
cyclin-dependent kinase 4 (also known as: U37022 or cdk4),
20 MEK5 (also known as: U25265 or Mitogen-activated protein kinase kinase 5),
MKP-L (gene accession number: NM_007026; also known as AF038844),
ADAM22 (gene accession number: NM_016351, a disintegrin and metalloproteinase domain 22, also known as AF155382),
ADAM17 (also known as: U92649 or a disintegrin and metalloproteinase domain
25 17 (tumor necrosis factor, alpha, converting enzyme) also known as XM_002270),
are specifically and uniquely up- or downregulated in a cell as a result of HCV infection. These cellular protein kinases, metalloproteases and the phosphatase therefore identify novel diagnostic and therapeutic targets for HCV infection.
- 30 The only reliable experimental HCV infection studies have been performed with chimpanzees. There is no simple cell culture infection system available for HCV. Although a number of reports have been published describing *in vitro* propagation attempts of HCV in primary cells and cell lines, questions remain concerning

reproducibility, low levels of expression and properly controlled detection methods (reviewed in J. Gen Virol. 81, 1631; Antiviral Chemistry and Chemotherapy 10, 99). Thus, the replicon system described by Bartenschlager and coworkers (Lohmann et al, Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110. 1999) was used for the studies disclosed herein. This replicon system reproduces a crucial part of the HCV replication cycle which is used as a system for simulating HCV infection. Bartenschlager's group produced bicistronic recombinant RNAs, so-called "replicons", which carry the Neomycin-phosphotransferase gene as well as a version of the HCV genome where the sequences for the structural HCV proteins were deleted. After transfection of the subgenomic HCV RNA molecules into the human hepatoma cell line Huh-7, cells supporting efficient RNA-dependent RNA replication of the HCV replicons were selected based on co-amplification of the neo gene and resulting resistance to the antibiotic G418. Integration of coding information into the cellular genome was an exclusion criterium for functional replicons. Several lines were established from G418 resistant clones with autonomously replicating HCV RNAs detectable by Northern blot. Minus-strand RNA replication intermediates were detected by Northern blot or metabolic radio-labeling, and the production of nonstructural HCV proteins was demonstrated by immuno-precipitation after metabolic labeling or Western blot.

Possible influences and/or dependencies of HCV's RNA-dependent RNA replication and nonstructural proteins on host cell transcription are accessible to analysis with the cDNA arrays used in the inventive methods described herein. Expression levels can be confirmed using Northern or Taqman analysis at the RNA and Western blot analysis at the protein level. Huh-pcDNA3 cells are Huh7 cells resistant to G418 by integration of a plasmid and serve as negative control. Three replicon lines were analyzed for changes in cellular RNA expression patterns compared to the control line:

- Huh-9-13: cell line with persistent replicon I377/NS3-3'/wt, described in Science 1999, 285, 110-113,
- Huh-5-15: cell line with persistent replicon I389/NS3-3'/wt, described in Science 1999, 285, 110-113,
- Huh-11-7: cell line with persistent replicon I377/NS2-3'/wt, described in Science 1999, 285, 110-113.

Based on the discoveries reported herein, one aspect of the present invention is directed to a screening method for detecting compounds useful for the prophylaxis and/or treatment of Hepatitis C virus infections. Specifically, this method involves

5 contacting a test compound with at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein

10 Kinase C, mu (X75756), Protein Kinase C, theta(L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (AF038844, NM_007026), ADAM22 (NM_016351), ADAM17 (U92649) and detecting the human cellular protein kinase, metalloprotease or phosphatase

15 activity.

Another aspect of the present invention is directed to a diagnostic method, an assay for detecting Hepatitis C virus infections in an individual or cells. This method involves providing a sample from the individual or providing cells and detecting

20 activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of: beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein

25 Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), ADAM17 (U92649) and detecting the human cellular protein kinase, metalloprotease or phosphatase activity.

30

Accordingly, one aspect of the present invention is directed to novel compounds useful in the above-identified methods. Therefore, the present invention relates to a monoclonal or polyclonal antibody that binds to a human cellular protein kinase,

metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein
5 Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351) and ADAM17 (U92649).

10 Furthermore, the present invention discloses a method for treating Hepatitis C virus infection in an individual comprising the step of administering a pharmaceutically effective amount of an agent which inhibits at least partially the activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from
15 the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4
20 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).

Another object of the present invention is to provide a method for regulating the production of Hepatitis C virus in cells comprising the step of administering a
25 pharmaceutically effective amount of an agent to said cells wherein said agent inhibits at least partially the activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1
30 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L

(NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649). The above-mentioned monoclonal or polyclonal antibodies directed against these targets may be used as pharmaceutically active agents within said methods.

- 5 In order to identify HCV infections and new inhibitors and new pharmaceutically active compounds against Hepatitis C viruses a further aspect of the present invention is directed to a solid support useful for detecting Hepatitis C virus infections in an individual or in cells comprising an immobilized oligonucleotide, wherein said oligonucleotide is capable of detecting activity of at least one human
- 10 cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated
- 15 protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649). Said solid support is also useful to screen compounds for the prophylaxis and/or treatment of Hepatitis C virus infections in an individual comprising at least one immobilized
- 20 oligonucleotide, wherein said oligonucleotide encodes one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein
- 25 Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649) or comprising at least one immobilized human cellular protein kinase, metalloprotease or
- 30 phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein

Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).

5

Yet another aspect of the present invention is directed to a novel therapeutic composition useful for the prophylaxis and/or treatment of an individual afflicted with Hepatitis C virus comprising at least one agent capable of inhibiting activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected
10 from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1 (NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759),
15 Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).

20 Detailed description of the invention

Utilizing microarray technology, a unique microarray of more than 900 signal transduction cDNAs was developed. This array was used to compare signal transduction mRNA expression patterns (e.g. upregulation or downregulation) from HCV Replicon cells Huh-9-13, Huh-5-15, and Huh-11-7 with Huh-pcDNA
25 control cells which do not contain HCV Replicons. These HCV Replicon cells serve as a system for simulation of HCV infected cell systems, especially for simulating HCV infected mammals, including humans. Interference of HCV with the cellular signaling events is reflected in differential gene expression when compared to cellular signaling in control cells. Results from this novel signal
30 transduction microarray analysis revealed significant up- or downregulation of human cellular protein kinases, metalloproteases and one phosphatase. Radioactively labeled complex cDNA-probes from HCV Replicon cells Huh-9-13, Huh-5-15, and Huh-11-7 were hybridized to cDNA-arrays and compared to

hybridizations with cDNA-probes from Huh-pcDNA control cells which did not contain HCV Replicons. Surprisingly it was found that the following cellular targets are significantly up- or downregulated:

	beta-adrenergic receptor kinase 1 (NM_001619):	2.7 – 3.5 fold stronger
5	Mitogen activated protein kinase activated protein kinase 5 (AF032437):	2.2 – 3.0 fold stronger
	Insulin-stimulated protein kinase 1 (U08316):	2.2 – 3.1 fold stronger
	TRK E (NM_013994):	3.2 -10.3 fold stronger
	Human p21-activated protein kinase 2 (U24153):	1.8 – 2.7 fold stronger
10	PKC-mu (X75756):	2.3 – 3.2 fold weaker
	PKC-theta (L01087):	2.6 – 3.3 fold weaker
	AMP-activated protein kinase beta 2 subunit (AJ 224538):	1.9 – 2.2 fold weaker
	JNK2 (U09759):	2.6 – 4.1 fold weaker
15	cdk4 (U37022)	1.8 – 3.3 fold stronger
	MEK5 (U25265)	0.9 – 3.6 fold stronger
	MKP-L (NM_007026):	2.1 – 2.3 fold weaker
	ADAM22 (NM_016351):	2.5 – 3.8 fold weaker
20	ADAM17 (U92649):	3.4 – 3.8 fold weaker

Disclosed herein is the first report describing the role of human cellular proteins beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1 (NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein

kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), ADAM17 (U92649) in the signal transduction of the HCV infection process. As a result of these discoveries, novel compounds and inhibitors against the above-mentioned human cellular protein
5 kinases, metalloproteases and phosphatases may be found by the use of the inventive methods disclosed herein.

ADAM17 and ADAM22 are proteins of the ADAM family (proteins containing a disintegrin and metalloprotease domain). ADAM17 is also known as "Homo
10 sapiens a disintegrin and metalloproteinase domain 17" and ADAM22 is known as "Homo sapiens metalloprotease-like, disintegrin-like, cysteine-rich protein 2 epsilon".

As used herein, the term "inhibitor" refers to any compound capable of
15 downregulating, decreasing, suppressing or otherwise regulating the amount and/or activity of the human cellular proteins beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1 (NM_013994), Protein Kinase C, mu (X75756), Protein
20 Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649). Generally, human cellular protein inhibitors may be proteins, oligo- and polypeptides, nucleic acids, small chemical
25 molecules, or other chemical moieties.

As used herein, the term "regulating expression and/or activity" generally refers to any process that functions to control or modulate the quantity or activity (functionality) of a cellular component. Static regulation maintains expression
30 and/or activity at some given level. Upregulation refers to a relative increase in expression and/or activity. Accordingly downregulation refers to a relative decrease in expression and/or activity. In the present invention, regulation is preferably downregulation of a cellular component. As used herein,

downregulation is synonymous with inhibition of a given cellular component's activity.

Therapeutics, pharmaceutically active agents or inhibitors, respectively, may be administered to cells from an individual *in vitro*, or may involve *in vivo* administration to the individual. The term "individual" preferably refers to mammals and most preferably to humans. Routes of administration of pharmaceutical preparations to an individual may include oral and parenteral, including dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical or transdermal application, but are not limited the these ways of administration. For instance, the preferred preparations are in administratable form which is suitable for oral application. These administratable forms, for example, include pills, tablets, film tablets, coated tablets, capsules, powders and deposits. Administration to an individual may be in a single dose or in repeated administrations, and may be in any of a variety of physiologically acceptable salt forms, and/or with an acceptable pharmaceutical carrier, binder, lubricant, excipient, diluent and/or adjuvant. Pharmaceutically acceptable salt forms and standard pharmaceutical formulation techniques are well known to persons skilled in the art.

As used herein, a "pharmaceutical effective amount" of a human cellular protein kinase, metalloprotease or phosphatase inhibitor is an amount effective to achieve the desired physiological result, either in cells treated *in vitro* or in a subject treated *in vivo*. Specifically, a pharmaceutically effective amount is an amount sufficient to inhibit, for some period of time, one or more of the clinically defined pathological processes associated with the viral infection. The effective amount may vary depending on the specific human cellular protein kinase, metalloprotease or phosphatase inhibitor selected, and is also dependent on a variety of factors and conditions related to the subject to be treated and the severity of the infection. For example, if the inhibitor is to be administered *in vivo*, factors such as the age, weight and health of the patient as well as dose response curves and toxicity data obtained in pre-clinical animal work would be among

those considered. If the inhibitor is to be contacted with the cells *in vitro*, one would also design a variety of pre-clinical *in vitro* studies to assess such parameters as uptake, half-life, dose, toxicity, etc. The determination of a pharmaceutically effective amount for a given agent is well within the ability of those skilled in the art.

It is also apparent to a person skilled in the art that detection includes any method known in the art useful to indicate the presence, absence, or amount of a detection target. Such methods may include, but are not limited to, any molecular or cellular techniques, used singularly or in combination, including, but not limited to: hybridization and/or binding techniques, including blotting techniques and immunoassays; labeling techniques (chemiluminescent, colorimetric, fluorescent, radioisotopic); spectroscopic techniques; separations technology, including precipitations, electrophoresis, chromatography, centrifugation, ultrafiltration, cell sorting; and enzymatic manipulations (e.g., digestion).

The present disclosure teaches for the first time the up- or downregulation of a group of human cellular protein kinases, metalloproteases and a phosphatase specifically involved in the viral infection of Hepatitis C virus. Thus, the present invention is also directed to a method useful for detecting novel compounds useful for prophylaxis and/or treatment of HCV infections.

Methods of the present invention identify compounds useful for prophylaxis and/or treatment of HCV infections by screening a test compound, or a library of test compounds, for its ability to inhibit any one or more of the group of human cellular protein kinases, metalloproteases or phosphatases identified herein as characteristically up- or downregulated during HCV growth and RNA replication inside a cell. A variety of assay protocols and detection techniques are well known in the art and easily adapted for this purpose by a skilled practitioner. Such methods include, but are not limited to, high throughput assays (e.g., microarray technology, phage display technology), and *in vitro* and *in vivo* cellular and tissue assays.

In a related aspect, the present invention provides, in view of the discovery of human cellular protein kinases, metalloproteases and phosphatases specifically involved in the HCV infection process, an assay component specially useful for detecting HCV in an individual or in cells. Preferably the assay component comprises oligonucleotides immobilized on a solid support capable of detecting activity of one or more of the human cellular protein kinases, metalloproteases or phosphatase comprising:

the kinases	beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1 (NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265);
the metalloproteases	ADAM22 (NM_016351), ADAM17 (U92649) and
the phosphatase	MKP-L (NM_007026).

20₀ Preferably the solid support would contain oligonucleotides of sufficient quality and quantity to detect all of the above-mentioned human cellular proteins (e.g., a nucleic acid microarray).

Similarly, it is an object of the present invention to provide an assay component
25 specially useful for screening compounds useful for the prophylaxis and/or
treatment of HCV infections. One preferred assay component comprises
oligonucleotides that encode one or more human cellular protein kinases: beta-
adrenergic receptor kinase (X61157), Mitogen activated protein kinase activated
protein kinase (AF032437), Insulin-stimulated protein kinase 1 (U08316), TRK E
30 (X74979), PKC-mu (X75756), PKC-theta (L01087), AMP-activated protein kinase
beta 2 subunit (AJ 224538), JNK2 (L31951), Human p21-activated protein kinase,
and PAK2 (U24153); or metalloproteases: ADAM22 (AF155382) and ADAM17

(XM_002270); or the Phosphatase MKP-L, (NM_007026) immobilized on a solid support.

5 In another embodiment, the assay component comprises peptide fragments of one or more of the above-identified human cellular proteins immobilized on a solid support. Once again the most preferred solid support embodiment would contain polymers of sufficient quality and quantity to detect all of the above-mentioned human cellular protein kinases, metalloproteases and the phosphatase (e.g., a nucleic acid or a peptide microarray). A variety of supports and constructions of
10 the same for the methods disclosed herein are well known in the art and easily adapted for this purpose by a skilled practitioner (cf., for example: Marschall, 1999 "Do-it-yourself gene watching" Science 286, 444-447; Service 2000 "Protein arrays step out of DNA's shadow" Science 289, 1673).

15 It is preferred that mRNA is measured as an indication of expression. Methods for assaying for mRNA include, but are not limited to, Northern blots, slot blots, dot blots, and hybridization to an ordered array of oligonucleotides. Nucleic acid probes useful for assay of a sample are preferably of sufficient length to specifically hybridize only to appropriate, complementary transcripts. Typically the
20 oligonucleotide probes will be at least 10 to 25 nucleotides in length. In some cases longer probes of at least 30, 40, or 50 up to 2500 nucleotides will be desirable.

The polypeptide product of gene expression may be assayed to determine the
25 amount of expression as well. Methods for assaying for a protein include, but are not limited to, western blot, immuno-precipitation, radioimmuno assay, and peptide immobilization in an ordered array. It is understood, however, that any method for specifically and quantitatively measuring a specific protein or mRNA product can be used.

30

A variety of supports upon which nucleic acids or peptides can be immobilized are known in the art, for example filters, or polyvinyl chloride dishes. Any solid surface to which oligonucleotides or peptides can be bound, either directly or indirectly,

either covalently or non-covalently, can be used. A preferred solid support is a microarray membrane filter or a "biochip". These contain particular polymer probes in predetermined locations on the array. Each predetermined location may contain more than one molecule of the probe, but each molecule within the
5 predetermined location has an identical sequence.

The present invention incorporates by reference in their entirety techniques well known in the field of molecular biology. These techniques include, but are not limited to, techniques described in the following publications:

- 10 Ausubel, F.M. et al. eds., "Short Protocols In Molecular Biology" 4th Ed. 1999, John Wiley & Sons, NY (ISBN 0-471-32938-X);
- Old, R.W. & S.B. Primrose "Principles of Gene Manipulation: An Introduction To Genetic Engineering" 3rd Ed. 1985, Blackwell Scientific Publications, Boston. Studies in Microbiology: V.2, 409 pp. (ISBN 0-632-01318-4);
- 15 Miller, J.H. & M.P. Calos eds., "Gene Transfer Vectors For Mammalian Cells" 1987, Cold Spring Harbor Laboratory Press, NY. 169 pp. (ISBN 0-87969-198-0);
- Mayer, R.J. & J.H. Walker eds. "Immunochemical Methods In Cell and Molecular Biology" 1987, Academic Press, London. 325 pp. (ISBN 0-12480-855-7);
- Sambrook, J. et al. eds., "Molecular Cloning: A Laboratory Manual" 2nd Ed. 1989,
20 Cold Spring Harbor Laboratory Press, NY. Vols. 1-3. (ISBN 0-87969-309-6);
- Winnacker, E.L. "From Genes To Clones: Introduction To Gene Technology" 1987 VCH Publishers, NY. (translated by Horst Ibelgaufts) 634 pp. (ISBN 0-89573-614-4).

25 The present invention further incorporates by reference in their entirety techniques well known in the field of microarray construction and analysis. These techniques include, but are not limited to, techniques described in the following patents and patent applications describing array of biopolymeric compounds and methods for their fabrication:

- 30 U.S. Pat. Nos. 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186;
5,429,807; 5,436,327; 5,445,934; 5,472,672; 5,527,681; 5,529,756;
5,545,531; 5,554,501; 5,556,752; 5,561,071; 5,559,895; 5,624,711;

5,639,603; 5,658,734; 5,807,522; 6,087,102; WO 93/17126; WO 95/11995; WO 95/35505; EP 742 287; and EP 799 897.

Techniques also include, but are not limited to, techniques described in the following patents and patent application describing methods of using arrays in various applications:

U.S. Pat. Nos. 5,143,854; 5,288,644; 5,324,633; 5,432,049;
5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839;
5,580,732; 5,661,028; 5,994,076; 6,033,860; 6,040,138; 6,040,140;
10 WO 95/21265; WO 96/31622; WO 97/10365; WO 97/27317;
EP 373 203; and EP 785 280

It is readily apparent to those skilled in the art that other suitable modifications and adaptations of the compositions and methods of the invention described herein are evident and may be made without departing from the scope of the invention or the embodiments disclosed herein. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting of the invention.

20

Examples

Materials and Methods

25

1. Generation of cDNA-arrays on membranes

In order to manufacture cDNAs-arrays on membranes, the following strategy was pursued: cDNAs encoding parts of or full length proteins of interest – in the following referred to as “target cDNAs” – were cloned into the plasmid Bluescript II KS⁺ (Stratagene, USA). Large scale purifications of these plasmids were performed according to standard techniques and 200 µl aliquots (1 µg/µl plasmid concentration) were transferred into appropriate 96 well plates. Plates were closed with sealing tape and chilled on ice for 5 minutes after incubation for 10 minutes at 95°C. 10 µl of 0.6N NaOH were added and the mix was stored for 20

30

minutes at room temperature before addition of 10 μ l 2.5M Tris-HCl pH 7.1 and 20 μ l 40x SSC. Target cDNAs were spotted onto Nylon or Nitrocellulose membranes using a BioGrid (BioRobotics, UK) equipped with a 0.7 mm pintool. In this way, between 200 ng and 350 ng of plasmids encoding target cDNAs were transferred
5 onto the membranes and crosslinked to the membranes by ultraviolet light ($1.2 \times 10^5 \mu\text{J}/\text{cm}^2$). The arrays were stored for use in subsequent experiments at at 4°C.

2. Cellular HCV RNA replication system

10 Huh-pcDNA3, Huh-9-13, Huh-5-15 and Huh-11-7 cells were grown in DMEM supplemented with 10% FCS, 2 mM Glutamine, Penicillin (100 IU/ml) / Streptomycin (100 $\mu\text{g}/\text{ml}$) and 1x nonessential amino acids in the presence of 1 mg/ml G418. Cells were routinely passaged three times a week at a dilution of 1:3 or 1:2.

3. Lysis of cells, and isolation of total RNA

15 Huh-pcDNA3, Huh-9-13, Huh-5-15 and Huh-11-7 cells were seeded at 5×10^5 cells per 10 cm plate in medium without G418. The medium was changed 3 days after plating and cells were harvested 5 days after plating by lysing the cells
20 directly on the plate with 4 ml of Tri reagent (Molecular Research Center, Inc., USA). The lysates were stored at room temperature for 5 minutes and then centrifuged at 12000xg for 15 minutes at 4°C. The supernatant was mixed with 0,1 ml of 1-Bromo-3-chloropropane per 1 ml of Tri reagent and vigorously shaken. The suspension was stored for 5 minutes at room temperature and then
25 centrifuged at 12000xg for 15 minutes at 4°C. The colorless upper phase was transferred into new tubes, mixed with 5 μ l of polyacryl-carrier (Molecular Research Center Inc., USA) and with 0.5 ml of isopropanol per 1 ml of Tri reagent and vigorously shaken. The samples were stored at room temperature for 5 minutes and then centrifuged at 12000xg for 8 minutes at 4°C. The supernatant
30 was removed and the RNA pellet washed twice with 1 ml of 75% Ethanol. The pellet was dried and resuspended in 25 μ l of RNase-free buffer per initial 1 ml lysate.

4. Preparation of radioactively labelled cDNA probes from RNA

In order to obtain a radioactively labeled cDNA probe, RNA was transcribed into a cDNA-probe in the presence of radioactively labeled dATP. 12 µl bidistilled DEPC treated H₂O containing 1 µg of primer TXN (5'-TTT TTT TTT TTT TTT TXN-3' with T → dTTP; N → dATP, dCTP, dGTP or dTTP; X → dATP, dCTP or dGTP) and total RNA (6 µg) were shaken between 5 and 15' at 60°C and then incubated at 4°C for 2 to 10 minutes. After centrifugation (30 seconds, 10000xg) 7 µl of a mix consisting of 100 µCi dATP-P³³ (Amersham, UK) which were dried under vacuum previously and resuspended in 4 µl first strand buffer (Life Technologies, USA), 2 µl 0.1M DTT and 1 µl labeling solution (4mM dCTP, dGTP, dTTP each and 80 µM dATP final concentration) were added. Following the addition of 1 µl Superscript II reverse transcriptase (Life Technologies, USA) the reaction was incubated for 10 minutes at room temperature and then for 60 minutes at 38°C. Subsequently, the reaction was vigorously shaken for 30 minutes at 68°C after adding 5 µl 0.5M EDTA and 25 µl 0.6M NaOH.

Unincorporated nucleotides were removed from the labeling reaction using ProbeQuant G-50 columns (Amersham, UK). The column was vigorously shaken and centrifuged for 1 minute at 735xg in an appropriate reaction tube after bottom closure and lid were removed. The column was placed into a new reaction tube, the probe was applied onto the center of the column material and the column was centrifuged for 2 minutes at 735xg. The flow-trough was transferred into new reaction tubes and filled up to a volume of 100 µl with 10mM Tris, pH 7.4, 1 mM EDTA. The probe was precipitated by centrifugation for 15 minutes at 12000xg after 4 µl of 5M NaCl, 1 µl polyacryl-carrier (Molecular Research Center Inc., USA) and 250µl Ethanol were added. The supernatant was discarded and the pellet dried before starting with the hybridisation.

30

5. Hybridisation of radioactively labeled cDNA-probes to cDNA-arrays

The pellet was resuspended in 10 µl C₀T DNA (1 µg/µl, Roche Diagnostics, Germany), 10 µl yeast tRNA (1 µg/µl Sigma, USA) and 10 µl polyA (1 µg/µl, Roche

Diagnostics, Germany). Herring sperm DNA was added to a final concentration of 100 µg/ml and the volume was filled up to 100 µl with 5 µl 10% SDS (Sodiumdodecylsulfat), 25 µl 20x SSPE and bidistilled H₂O. The mix was put on 95°C for 5 minutes, centrifuged for 30 seconds at 10000xg and vigorously shaken for 60 minutes at 65°C. A 1 µl aliquot of the probe was used to measure the incorporation of radioactive dATP with a scintillation counter. Probes with at least a total of 20x10⁶ cpm were used. The arrays were prehybridised for at least 3 hours at 65°C in hybridisation solution in a roller bottle oven. After prehybridisation the radioactively labeled probe was added into the hybridisation solution and hybridisation was continued for 20 hours. The probe was discarded and replaced with wash solution A (2xSSC). The arrays were washed twice in wash solution A at room temperature in the roller oven. Afterwards, wash solution A was replaced by wash solution B (2x SSC, 0.5% SDS) preheated to 65°C and arrays were washed twice for 30 minutes at 65°C. Then, wash solution B was replaced by wash solution C (0.5x SSC, 0.5% SDS) preheated to 65°C and arrays were washed twice for 30 minutes at 65°C. The moist arrays were wrapped in airtight bags and exposed for 8 to 72 hours on erased phosphorimager screens (Fujifilm, Japan).

20 6. Analysis of cDNA-arrays

The exposed phosphorimager screens were scanned with a resolution of 100 µ and 16bits per pixel using a BAS-1800 (Fujifilm, Japan). Files were imported into the computer program ArrayVision (Imaging Research, Canada). Using the program's features, the hybridisation signals of each target cDNA were converted into numbers. The strength of the hybridisation signals reflected the quantity of RNA molecules present in the probe. Differentially expressed genes were selected according to the ratio of their signal strength after normalization to the overall intensity of the arrays.

30

7. Analysis of expression levels by Northern blot experiment

Huh-pcDNA3, Huh-9-13, Huh-5-15 and Huh-11-7 cells were seeded at 5 x 10⁵ cells per 10 cm plate in medium without G148. Cells were harvested after 3 days

by lysing the cells directly on the plate with 4 ml of Tri reagent (Molecular Research Centre, Inc., USA). The lysates were stored at room temperature for 5 minutes and then centrifuged at 12000xg for 15 minutes at 4°C. The supernatant was mixed with 0,1 ml of 1-bromo-3-chloropropane per 1 ml of Tri reagent and vigorously shaken. The suspension was stored for 5 minutes at room temperature and then centrifuged at 12000xg for 15 minutes at 4°C. The colourless upper phase was transferred into new tubes, mixed with 5 µl of poly-acryl-carrier (Molecular Research Centre, Inc., USA) and with 0.5 ml of isopropanol per 1 ml of Tri reagent and vigorously shaken. The samples were stored at room temperature for 5 minutes and then centrifuged at 12000xg for 8 minutes at 4°C. The supernatant was removed and the RNA pellet washed twice with 1 ml of 75% Ethanol. The pellet was dried and resuspended in 25 µl of RNase-free water per initial 1 ml lysate. 8 µg of total RNA per sample was loaded onto formaldehyde-containing agarose gels (Sambrook et al. Cloning manual, CSHL press, 1989) and transferred to HYbond NX membranes (Amersham) overnight in 20x SSC (3M NaCl, 300mM C₆H₅Na₃O₇ x 2 H₂O, pH 7.0) by capillary transfer. RNA was immobilized to the filter using UV-crosslinking (120mJ/cm² for 25 seconds). Filters were hybridized to oligonucleotide probes or random-primed probes specific for the genes in question. Quantitation of signals was performed with a Fuji phosphoimager.

8. Verification of de-regulated genes by quantitative Real-Time PCR

Quantitative RT-PCR was used to verify hits resulting from DNA macroarray experiments by exploiting the 5'-exonuclease of Taq DNA polymerases to cleave the 5' fluorescent label of an oligonucleotide. Total RNA was extracted from cell lines (Qiagen RNeasy Mini Kit, QIAGEN, Hilden) and was reverse transcribed with Superscript II (Invitrogen, Karlsruhe) according to the manufacturer's protocol with 5 µg of RNA as a template and oligodT primers. Subsequently, the cDNA was analysed on a ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Darmstadt) with the 5'exonuclease assay by using the TaqMan Universal PCR Master Mix (#4324018, Applied Biosystems, Darmstadt) and non-extendible oligonucleotides. Gene-specific TaqMan probes were labelled with the reporter dye FAMTM at the 5'-end and the quencher dye TAMRATM at the 3' end of

the probe. GAPDH and 18SrRNA were used as reference genes with TaqMan probes that were labelled with VICTM and TAMRATM accordingly.

Experimental conditions were 2 minutes 50°C, 10 minutes 95°C, followed by 40 cycles with 15 seconds at 95°C and 1 minute at 60°C. Primer Express software
5 was used to design primers with a melting temperature of 58 - 60°C amplifying an amplicon of a maximum length of 150 bp.

9. Analysis of expression levels by Western blot experiments

Huh-pcDNA3, Huh-9-13, Huh-5-15 and Huh-11-7 cells were seeded at 5×10^5
10 cells per 10 cm plate in medium without G148. Cells were harvested after 3 days by the addition of 500 µl of 1x SDS sample buffer (62.5 mM Tris-HCl pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% bromphenol blue) or RIPA lysis buffer. Lysates were separated on SDS-poly acrylamide gels and proteins transferred to nitrocellulose. Western blotting was performed with the appropriate
15 antibodies according to the manufacturers instructions.

Claims

1. A method for detecting compounds useful for the prophylaxis and/or
5 treatment of Hepatitis C virus infections, the method comprising the following steps:
- a) contacting a test compound with at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619),
10 Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), ADAM17 (U92649); and
- 15 b) determining the activity of said human cellular protein kinase, metalloprotease or phosphatase.
- 20
2. A method for detecting Hepatitis C virus infections in an individual, the method comprising the following steps:
- a) providing a sample from said individual; and
- b) determining the activity in said sample of at least one human cellular
25 protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4
30

(U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).

3. A method for detecting Hepatitis C virus infections in cells, the method
5 comprising the following steps:
 - a) providing said cells; and
 - b) determining the activity in said cells of at least one human cellular
10 protein kinase, metalloprotease or phosphatase selected from the
group consisting of beta-adrenergic receptor kinase 1 (NM_001619),
Mitogen activated protein kinase activated protein kinase 5
(AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin
domain receptor family, member 1(NM_013994), Protein Kinase C,
mu (X75756), Protein Kinase C, theta (L01087), AMP-activated
protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human
15 p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4
(U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22
(NM_016351), and ADAM17 (U92649).
4. An antibody that binds to a human cellular protein kinase, metalloprotease or
20 phosphatase selected from the group consisting of beta-adrenergic receptor
kinase 1 (NM_001619), Mitogen activated protein kinase activated protein
kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin
domain receptor family, member 1(NM_013994), Protein Kinase C, mu
(X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase
25 beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein
kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265),
MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).
5. The antibody of claim 4, wherein said antibody is a monoclonal or polyclonal
30 antibody.
6. A method for treating Hepatitis C virus infection in an individual, the method
comprising the step of administering a pharmaceutically effective amount of an

- agent which inhibits at least partially the activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).
7. A method for regulating the production of Hepatitis C virus in cells, the method comprising the step of administering a pharmaceutically effective amount of an agent to said cells wherein said agent inhibits at least partially the activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).
8. The method according to claim 6 or 7, wherein the agent is an antibody which binds to at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein

kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).

- 5 9. The method according to claim 8, wherein said antibody is a monoclonal or polyclonal antibody.
- 10 10. A solid support useful for detecting Hepatitis C virus infections in an individual, the solid support comprising an immobilized oligonucleotide, wherein said oligonucleotide is capable of detecting activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).
- 20 11. A solid support useful for detecting Hepatitis C virus infections in cells, the solid support comprising an immobilized oligonucleotide, wherein said oligonucleotide is capable of detecting activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).
- 25 30

12. A solid support useful for screening compounds useful for the prophylaxis and/or treatment of Hepatitis C virus infections in an individual, the solid support comprising at least one immobilized oligonucleotide, wherein said oligonucleotide encodes one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).
13. A solid support useful for screening compounds useful for the prophylaxis and/or treatment of Hepatitis C virus infections in an individual, the solid support comprising at least one immobilized human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649).
14. A composition useful for the prophylaxis and/or treatment of an individual afflicted with Hepatitis C virus, the composition comprising at least one agent capable of inhibiting activity of at least one human cellular protein kinase, metalloprotease or phosphatase selected from the group consisting of beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein

Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and
5 ADAM17 (U92649).

10. Nucleic acid and amino acid sequences of human cellular proteins:

DEFINITION Homo sapiens adrenergic, beta, receptor kinase 1 (ADRBK1), mRNA.

5 ACCESSION NM_001619
EC number = "2.7.1.126"

10 DEFINITION Homo sapiens mitogen activated protein kinase activated protein kinase gene, complete cds.

15 ACCESSION AF032437
VERSION AF032437.1 GI:3133290
FEATURES Location/Qualifiers
source 1..1968
/organism="Homo sapiens"
/db_xref="taxon:9606"
20 CDS 192..1607
/note="MAPK-activated protein kinase; PRK"
/codon_start=1
/product="mitogen activated protein kinase activated protein kinase"
25 /protein_id="AAC39863.1"
/db_xref="GI:3133291"

/translation="MSEESDMDKAIKETSILEEYSINWTQKLGAGISGPVRVCVKKST
30 QERFALKILLDRPKARNEVRLHMMCATHPNIVQIIEVFANSVQFPHESSPRARLLIVM
EMMEGGELFHRISQHRHFTEKQASQVTKQIALALRHCHLLNIAHRDLKPENLLFKDNS
LDAPVKLCDFGFAKIDQGLMTPQFTPPYVAPQVLEAQRHQKEKSGIIPTSPTPTY
35 NKSCDLWSLGVIIYVMLCGYPPFYSKHHSRTIPKDMRRKIMTGSFEFPEEWSQISEM
AKDVVRKLLKVKPERRLTIEGVLDHPWLNSTEALDNVLPQAQLMMDKAVVAGIQQAHA
40 EQLANMRIQDLKVSLLKPLHSVNNPILRKRKLLGTPKDSVYIHDHENGAEEDSNVALEK
LRDVIAQCILPQAGENEDEKLNEVMQEAWKYNRECKLLRDTLQSFSWNGRGFTDKVDR
LKLAEIVKQVIEEQTTSHESQ"
BASE COUNT 571 a 445 c 485 g 467 t
45 ORIGIN
1 ccagcctaga gccgcccggc gaagcagagc cggcgccggg gtcctcatcc ccaccgggtcc
61 cgaggggagg ctgctgcccg tgcacacgag gccagggggc ccgagtgcgc agccctttgc
121 tccctcggcc gcgcggggac agggctgctg agcagcctcc gcctctcccg gctgtggggg
181 cccactgag tatgtcggag gagagcgaca tggacaaagc catcaaggaa acttccattt
50 241 tagaagaata cagtatcaat tggactcaga agctgggagc tggaattagt ggtccagtta
301 gagtctgtgt aaagaaatct actcaagaac ggtttgcgct gaaaattctt cttgatcgtc
361 caaaagctag aaatgaggta cgtctgcaca tgatgtgtgc cacacacca aacatagttc
421 agattattga agtgtttgct aacagtgtcc agtttcccca tgagtccagc cctagggccc
481 gactcttaat tgtaatggag atgatggaag ggggagagct atttcacaga atcagccagc
55 541 accggcactt tacagagaag caagccagcc aagtaacaaa gcagatagct ttggctctgc
601 ggcactgtca cttgttaaac attgcgcaca gagacctcaa gcctgaaaat ctgcttttta
661 aggataactc tttggatgcc ccagtgaagt tgtgtgactt tggatttgcc aagattgacc
721 aaggtgactt gatgacaccc cagttcaccc cttattatgt agcaccacag gtactggagg
781 cgcaaagaag gcatcagaag gagaaatctg gcatcatacc tacctcacag acgccctaca
60 841 cttacaacaa gagctgtgac ttgtgggtccc taggggtgat tatctatgtg atgctgtgag
901 gataccctcc tttttactcc aaacaccaca gccggactat cccaaaggat atgcgaagaa
961 agatcatgac aggcagtttt gacttcccag aggaagagtg gactcagatc tcagagatgg
1021 ccaaagatgt tgtgaggaag ctctgaagg tcaaacggga gaggagactc accatcgagg
1081 gagtgtctgga ccaccctgg ctcaattcca ccgaggccct ggataatgtg ctgccttctg

1141 ctcagctgat gatggacaag gcagtggttg caggaatcca gcagggtcac gcggaacagt
1201 tggccaacat gagaatccag gatctgaaag tcagcctcaa acccctgcac tcagtgaaca
1261 accccattct gcggaagagg aagttacttg gcaccaagcc aaaggacagt gtctatatcc
1321 acgaccatga gaatggagcc gaggattcca atgttgccct ggaaaaactc cgagatgtga
5 1381 ttgctcagtg tattctcccc caggctggag agaatgaaga tgagaaactg aatgaagtaa
1441 tgcaggaggc ttggaagtat aaccgggaat gcaaactcct aagagatact ctgcagagct
1501 tcagctggaa tggtcgtgga ttcacagata aagtagatcg actaaaactg gcagaaattg
1561 tgaagcaggt gatagaagag caaaccacgt cccacgaatc ccaataatga cagcttcaga
1621 ctttgttttt ttaacaattt gaaaaattat tctttaatgt ataaagtaat tttatgtaaa
10 1681 ttaataaatc ataatttcat ttccacattg attaaagctg ctgtatagat ttagggtgca
1741 ggacttaata atagtatagt tattgtttgt ttttaagaaa agctcagttc tagagacata
1801 ctattacttt aggactgtgt agttgtatat ttgtaagatg acagatgatg ctgtcaagca
1861 atattgtttt atttgtaata aaatatacaa aaatcacttg ccagcagtag aaaaaggacc
1921 gactataccg acctttctga ttagtaaaca gttgaatcaa ggactctg
15

20 DEFINITION Human insulin-stimulated protein kinase 1 (ISPK-1) mRNA,
complete

cds.

ACCESSION U08316

VERSION U08316.1 GI:475587

FEATURES Location/Qualifiers

25 source

1..2260

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="X"

/map="Xp21.3-22.1"

30

/clone_lib="MOLT 4 T-cell leukemia and human

placenta cDNA

libraries"

gene

1..2223

/gene="ISPK-1"

35

CDS

1..2223

/gene="ISPK-1"

/note="ribosomal protein S6 kinase"

/codon_start=1

/product="insulin-stimulated protein kinase 1"

40

/protein_id="AAA81952.1"

/db_xref="GI:475588"

/translation="MPLAQLADPWQKMAVESPSDSAENGQQIMDEPMGEEEEINPQTEE

45 VSIKEIAITHHVKEGHEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVL

KKATLKVDRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRL

50 KEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKES

IDHEKKAYSFCGTVEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGTLFPQGKDRKET

MTMILKAKLGMPQFLSPEAQSLRLMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNK

55 LYRREIHPPFKPATGRPEDTFYFDPEFTAKTPKDSPIPPSANAHQLFRGFSFVAITS

DDESQAMQTVGVHSIVQQLHRNSIQFTDGYEVKEDIGVGSYSVCKRCIHKATNMEFAV

60 KIIDKSKRDPTEIEILLRYGQHPNIITLKD VYDDGKYVYVVT ELMKGGELLDKILRQ

KFFSEREASAVLFTITKTVEYLHAQGVVHRDLKPSNILYVDESGNPESIRICDFGFAK

QLRAENGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGVLLYTMLTGYTPFANGPDD

TPEEILARIGSGKFSLSGGYWNSVSDTAKDLVSKMLHVDPHQRLTAALVLRHPWIVHW

DQLPQYQLNRQDAPHLVKGAMAATYSALNRNQSPVLEPVG RSTLAQRRGIKKITSTAL

5 BASE COUNT 704 a 417 c 510 g 629 t
ORIGIN

1 atgccgctgg cgcagctggc ggaccctggg cagaagatgg ctgtggagag cccgtccgac
61 agcgctgaga atggacagca aattatggat gaacctatgg gagaggagga gattaaccca
10 121 caaactgaag aagtcagtat caaagaaatt gcaatcacac atcatgtaaa ggaaggacat
181 gaaaaggcag atccttccca gtttgaactt ttaaaagtat tagggcaggg atcatttgga
241 aagggttttct tagttaaaaa aatctcaggc tctgatgcta ggcagcttta tgccatgaag
301 gtattgaaga aggccacact gaaagttcga gaccgagttc ggacaaaaat ggaacgtgat
361 atcttggttag aggttaataca tccttttatt gtcaagttgc attatgcttt tcaaactgaa
15 421 gggaagttgt atcttatttt ggattttctc aggggaggag atttgtttac acgcttatcc
481 aaagaggtga tgttcacaga agaagatgtc aaattctact tggctgaact tgcacttgct
541 ttagaccatc tacatagcct gggaataatt tatagagact taaaaccaga aaatatactt
601 cttgatgaag aaggtcacat caagttaaca gatttcggcc taagtaaaga gtctattgac
661 catgaaaaga aggcattatc tttttgtgga actgtggagt atatggctcc agaagtagtt
20 721 aatcgctcag gtcatactca gagtgtgac tgggtgtcct ttggtgtggt aatgtttgaa
781 atgcttactg gtacactccc ttccaagga aaagatcgaa aagaaacaat gactatgatt
841 cttaaaggca aacttggaaat gccacagttt ttgagtcctg aagcgcagag tcttttacga
901 atgcttttca agcgaatatc tgcaaacaga ttaggtgcag gaccagatgg agttgaagaa
961 attaaaagac attcattttt ctcaacgata gactggaata aactgtatag aagagaaatt
25 1021 catccgccat ttaaacctgc aacgggcagg cctgaagata cattctattt tgatcctgag
1081 tttactgcaa aaactcccaa agattcacct ggcatccac ctagtgtctt tgcacatcag
1141 ctttttcggg ggtttagtgt tgttgctatt acctcagatg atgaaagcca agctatgcag
1201 acagttagtg tacattcaat tgttcagcag ttacacagga acagtattca gtttactgat
1261 ggatatgaag taaaagaaga tattggagtt ggctcctact ctgtttgcaa gagatgtata
30 1321 cataaagcta caaacatgga gtttgacgtg aagattattg ataaaagcaa gagagacca
1381 acagaagaaa ttgaaattct tcttcgttat ggacagcatc caaacattat cactctaaag
1441 gatgtatatg atgatggaaa gtatgtgtat ttagtaacag aacttatgaa aggaggtgaa
1501 ttgctggata aaattcttag acaaaaattt ttctctgaac gagaggccag tgcgtcctg
1561 ttcactataa ctaaaaccgt tgaatatctt cagcacaag ggggtggttca tcgagacttg
35 1621 aaacctagca acattcttta tgtggatgaa tctggtaatc cggaatctat tcgaatttgt
1681 gattttggct ttgcaaaaca gctgagagcg gaaaatggtc ttctcatgac tccttggtac
1741 actgcaaatt ttgttgacc agaggtttta aaaagacaag gctatgatgc tgcttgatg
1801 atatggagtc ttggtgtcct actctataca atgcttaccg gttacactcc atttgcaaat
1861 ggtcctgatg atacaccaga ggaaatattg gcacgaatag gttagcgaaa attctcactc
40 1921 agtgggtggt actggaattc tgtttcagac acagcaaagg acctggtgtc aaagatgctt
1981 catgtagacc ctcatcagag actgactgct gctctgtgac tcagacatcc ttggatcgtc
2041 cactgggacc aactgccaca ataccaacta aacagacagg atgcaccaca tctagtaaag
2101 ggtgccatgg cagctacata ttctgctttg aaccgtaatc agtcaccagt tttggaacca
2161 gtaggccgct ctactcttgc tcagcggaga ggtattaaaa aaatcacctc aacagccctg
45 2221 tgaagtgacc tcagttagat atttggatcc atgggtgtaa

50 DEFINITION Homo sapiens discoidin domain receptor family, member 1 (DDR1),

transcript variant 3, mRNA.

ACCESSION NM_013994

VERSION NM_013994.1 GI:7669484

55 EC number = "2.7.1.112"

60

DEFINITION H.sapiens mRNA for protein kinase C mu.

ACCESSION X75756

VERSION X75756.1 GI:438372

FEATURES Location/Qualifiers

source 1..3742
/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="placenta"
5 CDS 236..2974
/codon_start=1
/product="protein kinase C mu"
/protein_id="CAA53348.1"
/db_xref="GI:438373"
10 /db_xref="SWISS-PROT:Q15139"
/translation="MSAPPVLRPPSPLLPVAAAAAAAAAALVPGSGPGPAPFLAPVAA
PVGGISFHLQIGLSREPVLLLQDSSGDYSLAHVREMACSIVDQKFPECIFYGMYDKIL
15 LFRHDPTSENILQLVKAASDIQEGDLIEVVLSRSATFEDFQIRPHALFVHSYRAPAFC
DHCGEMLWGLVRQGLKCEGCGLNYHKRCAPKIPNNCSGVRRLSNVSLTGVSTIRTS
20 SAELSTSAPDEPLLQKSPSEFIGREKRSNSQSYIGRPIHLDKILMSKVVPHTFVIH
SYTRPTVCQYCKLLKGLFRQGLQCKDCRFNCHKRCAPKVPNNCLGEVTINGDLLSPG
AESDVVMEEGSDDNDSENRSGLMDDMEEAMVQDAEMAMAECQNDSGEMQDPDPDHEDA
25 NRTISPSTSNNIPLMRVVQSVKHTKRKSSTVMKEGWMVHYTSKDTLRKRHYWRLDSKC
ITLQNDTGSRYKEIPLSEILSLEPVKTSALIPNGANPHCFEITTANVVVYVGENVV
30 NPSSPSPNNSVLTSVGADVARMWEIAIQHALMPVIPKGSSVGTGTNLHRDISVSISV
SNCQIQENVDISTVYQIFPDEVLGSGQFGIVYGGKHKRKTGRDVAIKIIDKLRFPTKQE
SQLRNEVAILQNLHHPGVVNLECMFETPERVFVMEKLGDMLEMILSSEKGRLEPHI
35 TKFLITQILVALRHLHFKNIVHCDLKPENVLLASADPFQVKLCDFGFARIIGESFR
RSVVGTPAYLAPEVLRNKGYNRSLDMWSVGVIIYVSLSGTFPFNEDEDIHDQIQNAAF
40 MYPPNPWKEISHEAIDLINLLQVKMRKRYSDKTLSPWLQDYQTWLRLRELECKIG
ERYITHESDDLWEKYAGEQRLQYPHTLINPSASHSDTPETEEMKALGERVSIL"
BASE COUNT 1015 a 897 c 865 g 965 t

45 ORIGIN

1 gaattccttc tctcctcctc ctgcgccttc tctcgccttc cctcctcctc ctgcgccttc
61 cctcccgatc ctcatccctc tgccctcccc cagcccaggg acttttcggg aaagttttta
121 ttttccgtct gggctctcgg agaaagaagc tctgggtca gcggtgcaa aactttcctg
181 ctgccgcgcc gccagcccc gccctccgct gcccgccct gcgccccgcc gagcgatgag
50 241 cgccctccg gtccctcgcc cgcctcagtc gctgctgcc gtggcgccg cagctgccgc
301 agcgccgcc gcactggtc cagggtccgg gcccgggccc gcgcccgttc tggctcctgt
361 cgcggccccc gtccggggca tctcgttcca tctgcagatc ggcctgagcc gtgagccgt
421 gctgctgtc caggactcgt ccgggggacta cagcctggcg cagctccgc agatggctt
481 ctccattgtc gaccagaagt tccctgaatg tggtttctac ggaatgtatg ataagatcct
55 541 gctttttcgc catgacccta cctctgaaaa catccttcag ctggtgaaag cggccagtga
601 tatccaggaa ggcgatctta ttgaagtggc cttgtcacgt tccgccacct ttgaagactt
661 tcagattcgt cccacgctc tctttgttca ttcatacaga gtcacagct tctgtgatca
721 ctgtggagaa atgctgtggg ggctggtacg tcaaggtctt aaatgtgaag ggtgtggtc
781 gaattaccat aagagatgtg catttaaaat acccaacaat tgcagcggtg tgaggcggag
841 aaggctctca aacgtttccc tccctggggc cagcaccatc cgcacatcat ctgctgaact
901 ctctacaagt gccctgatg agcccttctt gcaaaaatca ccatcagagt cgtttattgg
961 tcgagagaag aggtcaaatt ctcaatcata cattggacga ccaattcacc ttgacaagat
1021 tttgatgtct aaagttaaag tgccgcacac atttgtcatc cactcctaca cccggcccac
1081 agtgtgccag tactgcaaga agcttctgaa ggggcttttc aggcagggct tgcagtgcaa

```

1141 agattgcaga ttcaactgcc ataaacgttg tgcaccgaaa gtaccaaaaca actgccttgg
1201 cgaagtgacc attaatggag atttgcttag ccctggggca gagtctgatg tggatcatgga
1261 agaagggagt gatgacaatg atagtgaag gaacagtggg ctcattggatg atattggaaga
1321 agcaatggtc caagatgcag agatggcaat ggcagagtgc cagaacgaca gtggcgagat
5 1381 gcaagatcca gaccagacc acgaggacgc caacagaacc atcagtccat caacaagcaa
1441 caatatccca ctcattgagg tagtgagtc tgtcaaacac acgaagagga aaagcagcac
1501 agtcatgaaa gaaggatgga tgggtccacta caccagcaag gacacgctgc ggaaacggca
1561 ctattggaga ttggatagca aatgtattac cctctttcag aatgacacag gaagcaggtg
1621 ctacaaggaa attcctttat ctgaaatttt gtctctggaa ccagtaaaaa cttcagcttt
10 1681 aattcctaatt ggggccaatc ctcattgttt cgaaatcact acggcaaatg tagtgtatta
1741 tgtggggagaa aatgtggtca atccttccag cccatcacca aataacagtg ttctcaccag
1801 tggcggttgg gcagatgtgg ccaggatgtg ggagatagcc atccagcatg cccttatgcc
1861 cgtcattccc aagggtcct ccgtgggtac aggaaccaac ttgcacagag atatctctgt
1921 gagtatttca gtatcaaatt gccagattca agaaaatgtg gacatcagca cagtatatca
15 1981 gatttttcct gatgaagtac tgggttctgg acagtttggg attgtttatg gaggaaaaaca
2041 tcgtaaaaaa ggaagagatg tagctattaa aatcattgac aaattacgat ttccaacaaa
2101 acaagaaagc cagcttcgta atgaggttgc aattctacag aaccttcac accctgggtg
2161 tgtaaatatt gagtgtatgt ttgagacgcc tgaaagagtg tttgttgtta tggaaaaact
2221 ccatggagac atgctggaaa tgatcttgtc aagtgaanaa ggcaggttgc cagagcacat
20 2281 aacgaagttt ttaattactc agatactcgt ggctttgcgg caccttcatt ttaaaaaat
2341 cgttctactg gacctcaaac cagaaaatgt gttgctagcc tcagctgac tctttcctca
2401 ggtgaaactt tgtgattttg gtttggcccg gatcattgga gagaagtctt tccggaggtc
2461 agtgggtggg acccccgctt acctggctcc tgaggtccta aggaacaagg gctacaatcg
2521 ctctctagac atgtggtctg ttggggtcat catctatgta agcctaagcg gcacattccc
25 2581 atttaatgaa gatgaagaca tacacgacca aattcagaat gcagctttca tgtatccacc
2641 aaatccctgg aaggaaatat ctcatgaagc cattgatctt atcaacaatt tgcgtcaagt
2701 aaaaatgaga aagcgctaca gtgtggataa gaccttgagc cacccttggc tacaggacta
2761 tcagacctgg ttagatttgc gagagctgga atgcaaaatc ggggagcgtc acatcaccca
2821 tgaaagtgat gacctgaggt gggagaagta tgcaggcgag cagcggctgc agtaccacac
30 2881 acacctgatc aatccaagtg ctagccacag tgacactcct gagactgaag aaacagaaat
2941 gaaagccctc ggtgagcgtg tcagcatcct ctgagttcca tctcctataa tctgtcaaaa
3001 cactgtggaa ctaataaata catacggtca ggtttaacat ttgccttgca gaactgccat
3061 tattttctgt cagatgagaa caaagctgtt aaactgttag cactgttgat gtatctgagt
3121 tgccaagaca aatcaacaga agcatttgtg ttttgtgtga ccaactgtgt tgtattaaca
35 3181 aaagttccct gaaacacgaa acttgttatt gtgaatgatt catgttatat ttaatgcatt
3241 aaacctgtct ccactgtgcc tttgcaaatc agtgttttct ttactggagc ttcatttttg
3301 taagagacag aatgtatctg tgaagtagtt ctgtttgggtg tgtcccattg gtgtgtcat
3361 tgtaaacaaa ctcttgaaga gtcgattatt tccagtgttc tatgaacaac tccaaaaccc
3421 atgtgggaaa aaaatgaatg aggaggttag ggaataaaat cctaagacac aaatgcatga
40 3481 acaagtttta atgtatagtt ttgaatcctt tgcctgacct gtgtgcctca gtatatttaa
3541 actcaagaca atgcacctag ctgtgcaaga cctagtgtct ttaagcctaa atgccttaga
3601 aatgtaaact gccatatata acagatacat ttccctcttt cttataatac tctgtgttac
3661 tatggaaaat cagctgctca gcaacctttc acctttgtgt atttttcaat aataaaaaat
3721 attcttgtca aaaaaaaaaa aa
45

```

```

50 DEFINITION Human protein kinase C-theta (PRKCT) mRNA, complete cds.
ACCESSION L01087
VERSION L01087.1 GI:558098
FEATURES
    source 1..2754
            /organism="Homo sapiens"
55         /db_xref="taxon:9606"
            /cell_line="HEL"
            /cell_type="erythroleukemia"
            /tissue_lib="HEL cell lambda-gt11 library of M.
Poncz"
60     gene 95..2215
            /gene="PRKCT"
            CDS 95..2215
            /gene="PRKCT"
            /codon_start=1

```

/product="protein kinase C-theta"
 /protein_id="AAA75571.1"
 /db_xref="GI:558099"

```

5  /translation="MSPFLRIGLSNFDGSCQSCQGEAVNPYCAVLVKEYVESENGQM
   YIQKKPTMYPPWDSTFDAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCCKNNKG
   TEIWLELKPQGRMLMNARYFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCH
10  EFTATFFPQPTFC SVCHEFVWGLNKQGYQCRQCNAAIHKKCIDKVIKCTGSAINSRE
   TMFHKERFKIDMPHRFKVYNYKSPTFCEHCGLLWGLARQGLKCDACGMNVHHRQCQTK
15  VANLCGINQKLMAEALAMIESTQQARCLRDTEQIFREGPVEIGLPCSIKNEARLPCLP
   TPGKREPQGISWESPLDEVDKMCHLPEPELNKERPSLQIKLKIEDFILHKMLGKGSFG
   KVFLAEFKKTNQFFAIKALKKDVLMDDDVECTMVEKRVLSLAWEHPFLTHMFCTFQT
20  KENLFFVMEYLNCGDLMYHIQSCHKFDLSRATFYAAEIIILGLQFLHSGIVYRDLKLD
   NILLDKDGHIKIADFGMCKENMLGDAKTNTFCGTPDYLAPEILLGQKYNHSDVWSFG
25  VLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPRWLEKEAKDLLVKLFVREPEKRLGV
   RGDIRQHPLFREINWHEELERKEIDPPFRPKVKS PFDCSNFDKEFLNEKPRLSFADRAL
   INSMQNMFRNFSFMNPRMERLIS"
   BASE COUNT      764 a      657 c      686 g      647 t
30  ORIGIN
   1  gaattccgcc agccccgcca gtccccgcgc agtccccgcg cagtcccagc gccaccgggc
   61 agcagcggcg cegtgcctgc tccagggcgc aaccatgtcg ccatttcttc ggattggctt
   121 gtccaacttt gactgcgggt cctgccagtc ttgtcagggc gaggctgtta acccttactg
   181 tgctgtgctc gtcaaagagt atgtcgaaatc agagaacggg cagatgtata tccagaaaaa
35  241 gcctaccatg taccaccctt gggacagcac ttttgatgcc catatcaaca agggaagagt
   301 catgcagatc atttgtgaaag gcaaaaacgt ggacctcatc tctgaaacca ccgtggagct
   361 ctactcgctg gctgagaggt gcaggaagaa caacgggaag acagaaatat ggttagagct
   421 gaaacctcaa ggccgaatgc taatgaatgc aagatacttt ctggaaatga gtgacacaaa
   481 ggacatgaat gaatttgaga cggaaggctt ctttgccttg catcagcgcc ggggtgccat
40  541 caagcaggca aaggtccacc acgtcaagtg ccacgagttc actgccacct tctcccaca
   601 gcccacattt tgctctgtct gccacgagtt tgtctggggc ctgaacaaac agggctacca
   661 gtgccgacaa tgcaatgcag caattcacaa gaagtgtatt gataaagtta tagcaaagtg
   721 cacaggatca gctatcaata gccgagaaac catgttccac aaggagagat tcaaaattga
   781 catgccacac agatttaaag tctacaatta caagagcccg accttctgtg aacactgttg
45  841 gaccctgtcg tggggactgg cacggcaagg actcaagtgt gatgcattg gcatgaatg
   901 gcatcataga tgccagacaa aggtggccaa cctttgtggc ataaaccaga agctaattgc
   961 tgaagcgctg gccatgattg agagcactca acaggctcgc tgcttaagag atactgaaca
1021 gatcttcaga gaaggtccgg ttgaaattgg tctcccatgc tccatcaaaa atgaagcaag
1081 gctgccatgt ttaccgacac cgggaaaaag agagcctcag ggcatttcct gggagtctcc
50  1141 gttggatgag gtggataaaa tgtgccatct tccagaacct gaactgaaca aagaaagacc
   1201 atctctgcag attaaactaa aaattgagga ttttatcttg cacaaaatgt tggggaaagg
   1261 aagttttggc aaggtcttcc tggcagaatt caagaaaacc aatcaatttt tcgcaataaa
   1321 ggccttaaag aaagatgttg tcttgatgga cgatgatgtt gagtgcacga tggtagagaa
1381 gagagtctct tccttggcct gggagcatcc gtttctgacg cacatgtttt gtacatttca
55  1441 gaccaaggaa aacctctttt ttgtgatgga gtacctcaac ggaggggact taatgtacca
   1501 catccaaagc tgccacaagt tcgaccttcc cagagcgacg ttttatgctg ctgaaatcat
   1561 tcttggctcg cagttccttc attccaaagg aatagtctac agggacctga agctagataa
   1621 catcctgtta gacaaagatg gacatatcaa gatcgcggat tttggaatgt gcaaggagaa
   1681 catgttagga gatgccaaag cgaataacct ctgtgggaca cctgactaca tcgccccaga
60  1741 gatcttgctg ggtcagaaat acaaccactc tgtggactgg tggctcctcg gggttctcct
   1801 ttatgaaatg ctgattgggc agtcgccttt ccacgggcag gatgaggagg agctcttcca
   1861 ctccatccgc atggacaatc ccttttacct acggtggctg gagaagggaag caaaggacct
   1921 tctgggtgaag ctcttcgtgc gagaacctga gaagaggctg ggcgtgaggg gagacatccg
   1981 ccagcacctt ttgtttcggg agatcaactg ggaggaactt gaacggaagg agattgacct

```

```
2041 accgttccgg ccgaaagtga aatcaccatt tgactgcagc aatttcgaca aagaattctt
2101 aaacgagaag ccccggtgtg catttgccga cagagcactg atcaacagca tggaccagaa
2161 tatgttcagg aacttttcct tcatgaaccc ccgatggag cggctgatat cctgaatctt
2221 gccctccag agacaggaaa gaatttgcct tgtccctggg aactggttca agagacactg
5 2281 cttgggttcc tttttcaact tggaaaaaga aagaaacact caacaataaa gactgagacc
2341 cgttcgcccc catgtgactt ttatctgtag cagaaaccaa gtctacttca ctaatgacga
2401 tgccgtgtgt ctgctctcct gacatgtctc acagacgctc ctgaagttag gtcattacta
2461 accatagtta tttacttgaa agatgggtct ccgacttgg aaaggtttca agacttgata
2521 ctgcaataaa ttatggctct tcacctgggc gccaaactgct gatcaacgaa atgcttggtg
10 2581 aatcaggggc aaacggagta cagacgtctc aagactgaaa cggccccatt gcctggtcta
2641 gtagcggatc tcaactcagcc gcagacaagt aatcactaac ccgttttatt ctattcctat
2701 ctgtggatgg gtaaagtctg ggggccagcc ctggataggt ttttatggga attc
```

15

```
DEFINITION Homo sapiens mRNA for AMP-activated protein kinase beta 2
subunit.
ACCESSION AJ224538
20 VERSION AJ224538.1 GI:2916801
FEATURES Location/Qualifiers
    source          1..819
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
25     gene          1..819
                    /gene="AMPK beta 2"
    CDS             1..819
                    /gene="AMPK beta 2"
                    /function="regulatory subunit"
30     /codon_start=1
                    /evidence=experimental
                    /product="AMP-activated protein kinase beta 2
subunit"
                    /protein_id="CAA12030.1"
35     /db_xref="GI:2916802"
                    /db_xref="SWISS-PROT:O43741"
```

```
/translation="MGNTTSDRVSGERHGAKAARSEGAGGHAPGKEHKIMVGSTDDPS
40 VFSLPDSKLPDKEFVSWQQDLEDSVKPTQQARPTVIRWSEGGKEVFISGSFNNWSTK
IPLIKSHNDFVAILDLPEGEHQYKFFVDGQVHDPSEPVVTSQLGTINNLIHVKKSDF
EVDALKLDSESETSCRDLSPPPGPYGQEMYAFRSEERFKSPPIPPHLLQVILN
45 KDTNISCDPALLPEPNHVMLNHLIALSIKDSVMVLSATHRYKKKYVTTLLYKPI"
BASE COUNT      208 a      215 c      197 g      199 t
```

```
ORIGIN
50   1 atgggaaaca ccaccagcga cggggtgtcc ggggagcgcc acggcgccaa ggctgcacgc
   61 tccgagggcg caggcgcca tgcccgggg aaggagcaca agatcatggt ggggagtacg
  121 gacgaccca gcgtgttcag cctccctgac tccaagctcc ctggggacaa agagtgtgta
  181 tcatggcagc aggatttggg ggactccgta aagccacac agcaggcccg gccactgtt
  241 atccgctggt ctgaaggagg caaggaggtc ttcatctctg ggtctttcaa caattggagc
55  301 accaagattc cactgattaa gagccataat gactttgttg ccatcctgga cctccctgag
  361 ggagagcacc aatacaagtt ctttgtggat ggacagtggg ttcatgatcc atcagagcct
  421 gtggttacca gtcagcttgg cacaattaac aatttgatcc atgtcaagaa atctgatttt
  481 gaggtgttcg atgctttaaa gttagattct atggaaagt ctgagacatc ttgtagagac
  541 ctttccagct cacccccagg gccttatggt caagaaatgt atgcgtttcg atctgaggaa
60  601 agattcaaat cccacccat ccttctcct catctacttc aagttattct taacaaagac
  661 actaatattt cttgtgaccc agccttactc cctgagccca accatgttat gctgaaccat
  721 ctctatgcat tgtccattaa ggacagtgtg atggtcctta gcgcaaccca tcgctacaag
  781 aagaagtatg ttactactct gctatacaag cccatttga
```

DEFINITION Human protein kinase (JNK2) mRNA, complete cds.

5 ACCESSION U09759
VERSION U09759.1 GI:607785

FEATURES
 source Location/Qualifiers
 1..1873
 /organism="Homo sapiens"
10 gene /db_xref="taxon:9606"
 152..1426
 /gene="JNK2"
 CDS 152..1426
 /gene="JNK2"
15 /codon_start=1
 /product="protein kinase"
 /protein_id="AAA74740.1"
 /db_xref="GI:607786"

20 /translation="MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAF
DTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPOKTLLEEFQ
DVYLVMEMLMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVK
25 SDCTLKILDFGLARTACTNFMMPYVVTRYRAPEVILGMGYKENVDIWSVGCIMGEL
VKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFP
30 DWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPP
PQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPPDAAVSSNATPSQSSS
INDISSMSTEQTLASDSTDSSLDASTGPLEGCR"

BASE COUNT 562 a 388 c 427 g 496 t

35 ORIGIN
 1 caaactacgt gctgtacagc tgcatacagc gctcgtagac atgtccagca gctgggtcgag
 61 gtccacgccg cggtaggtga agttgcccga ggtccggcga gggatctgaa acttgcccct
 121 tacccttcgg gatattgcag gacgctgcat catgagcgcac agtaaatgtg acagtcagtt
 181 ttatagtgtc caagtggcag actcaacctt cactgtccta aaacgttacc agcagctgaa
40 241 accaattggc tctggggccc aagggattgt ttgtgctgca tttgatacag ttcttgggat
 301 aaatggtgca gtcaagaaac taagccgtcc ttttcagaac caaactcatg caaagagagc
 361 ttatcgtgaa cttgtcctct taaaatgtgt caatcataaa aatataatta gtttgttaaa
 421 tgtgtttaca ccacaaaaaa ctctagaaga atttcaagat gtgtatttgg ttatggaatt
 481 aatggatgct aacttatgtc aggttattca catggagctg gatcatgaaa gaatgtccta
45 541 ccttcctttac cagatgcttt gtgggtattaa acatctgcat tcagctggta taattcatag
 601 agatttgaag cctagcaaca ttgttgtgaa atcagactgc accctgaaga tccttgactt
 661 tggcctggcc cggacagcgt gcactaactt catgatgacc ccttacgtgg tgacacggta
 721 ctaccgggcg cccgaagtca tcctgggtat gggctacaaa gagaacgttg atatctggtc
 781 agtgggttgc atcatgggag agctgggtgaa aggttgtgtg atattccaag gcatgacca
50 841 tattgatcag tggaataaag ttattgagca gctgggaaca ccatcagcag agttcatgaa
 901 gaaacttcag ccaactgtga ggaattatgt cgaaaacaga ccaaagtatc ctggaatcaa
 961 atttgaagaa ctctttccag attggatatt cccatcagaa tctgagcgcag acaaaataaa
1021 aacaagtcaa gccagagatc tgttatcaaa aatgttagtg attgatcctg acaagcggat
1081 ctctgtagac gaagctctgc gtcacccata catcactgtt tggatagacc ccgccgaagc
55 1141 agaagcccca ccacctcaaa tttatgatgc ccagttggaa gaaagagaac atgcaattga
 1201 agaatggaaa gagctaattt acaaagaagt catggattgg gaagaaagaa gcaagaatgg
 1261 tgttgtaaaa gatcagcctc cagatgcagc agtaagtagc aacgccactc cttctcagtc
 1321 ttcacgcatc aatgacattt catccatgct cactgagcag acgctggcct cagacacaga
 1381 cagcagtcct gatgcctcga cgggacccct tgaaggctgt cgatgatagg ttagaaatag
60 1441 caaacctgtc agcattgaag gaactctcac ctccgtgggc ctgaaatgct tgggagttga
 1501 tggaacaaaa tagaaaaact ccatgttctg catgtaagaa acacaatgcc ttgccctact
 1561 cagacctgat aggattgcct gcttagatga taaaatgagg cagaatatgt ctgaagaaaa
 1621 aaattgcaag ccacacttct agagattttg ttcaagatca tttcagttga gcagttagag
 1681 taggtgaatt tgtcaaattg tactagtgc agtttctcat catctgtaac tgttgagatg

1741 attgtgcatg tgaccacaaa tgcttgcttg gacttgccca tctagcactt tggaaatcag
1801 tattttaaatg ccaaataatc ttccaggtag tgctgcttct gaagtatatct cttaatcctc
1861 ttaagtaatt tgg

5

DEFINITION Human p21-activated protein kinase (Pak2) gene,
complete cds.

10 ACCESSION U24153
VERSION U24153.1 GI:780807
FEATURES Location/Qualifiers
source 1..2019
/organism="Homo sapiens"
15 /db_xref="taxon:9606"
/clone="212"
/cell_type="EBV-transformed peripheral lymphocytes"
/clone_lib="lambdayESR human lymphocyte cDNA"
library;
20 Elledge and Spottswood, EMBO 10:2653(1991)"
gene 40..1617
/gene="Pak2"
CDS 40..1617
/gene="Pak2"
25 /codon_start=1
/product="p21-activated protein kinase"
/protein_id="AAA65442.1"
/db_xref="GI:780808"
30 /translation="MSDNGELEDKPPAPPVRMSSTIFSTGGKDPLSANHSLKPLPSVP
EEKKPRHKLIISIFSGTEKSGSKKKEKERPEISPPSDFEHTIHVGFDAVTGEFTGMPEQW
ARLLQTSNITKLEQKKNPQAVLDVLKFYDSNTVKQKYLSTPPEKDGLPSGTPALNAK
35 GTEAPAVVTEEEDDDEETAPPVIAPRPDHTKSIYTRSVDPVPAPVGDSHVDGAAKSL
DKQKKKPKMTDEEIMEKLRTIVSIGDPKKKYTRYEKIGQGASGTVFTATDVALGQEV
40 IKQINLQKQPKKELINEILVMKELKNPNIVNFLDSYLVGDELFFVMEYLAGGSLTDV
VTETACMDEAQIAAVCRECLQALEFLHANQVIHRDIKSDNVLLGMEGSVKLTDGFCA
QITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMVEGEPPYLNENPL
45 RALYLIATNGTPELQNPKEKLSPIFRDFLNRCLMDVEKRGSAKELLQHPFLKLAKPLS
SLTPLIMAAKEAMKSNR"
BASE COUNT 615 a 413 c 481 g 510 t

50 ORIGIN

1 gaccttggct tgcccggggc catttcataa ttctgaatca tgtctgataa cggagaactg
61 gaagataagc ctccagcacc tcctgtgcga atgagcagca ccatcttttag cactggaggc
121 aaagaccctt tgtcagccaa tcacagtttg aaacctttgc cctctgttcc agaagagaaa
181 aagcccaggc ataaaatcat ctccatattc tcaggcacag agaaaggaag taaaaagaaa
55 241 gaaaaggaac ggccagaaat ttctcctcca tctgattttg agcacaccat ccatgttggc
301 tttgatgctg ttactggaga attcactggc atgccagaac agtgggctcg attactacag
361 acctccaata tcaccaaact agagcaaaag aagaatcctc aggctgtgct ggatgtccta
421 aagttctacg actccaacac agtgaagcag aaatatctga gctttactcc tcctgagaaa
481 gatggccttc cttctggaac gccagcactg aatgccaaagg gaacagaagc acccgcgagta
60 541 gtgacagagg aggaggatga tgatgaagag actgctcctc ccgttattgc cccgcgaccg
601 gatcatacga aatcaattta cacacggctc gtaattgacc ctgttcctgc accagtgggt
661 gattcacatg ttgatgggtg tgccaagtct ttagacaaac agaaaaagaa gcctaagatg
721 acagatgaag agattatgga gaaattaaga actatcgtga gcataggtga ccctaagaaa


```

      781 aaatatacaa gatatgaaaa aattggacaa ggggcttctg gtacagtttt cactgctact
      841 gacgttgacac tgggacagga ggttgctatc aaacaaatta atttacagaa acagccaaag
      901 aaggaactga tcattaacga gattctgggtg atgaaagaat tgaaaaatcc caacatcggt
      961 aacttttttg acagttacct ggtaggagat gaattgtttg tggatcatgga ataccttgct
5  1021 ggggggtcac tcaactgatgt ggtaacagaa acagcttgca tggatgaagc acagattgct
      1081 gctgtatgca gagagtgttt acaggcattg gagtttttac atgctaataca agtgcaccac
      1141 agagacatca aaagtgacaa tgtacttttg ggaatggaag gatctgttaa gctcactgac
      1201 tttgggtttct gtgcccagat cacccttgag cagagcaaac gcagtaccat ggtcggaacg
      1261 ccatactgga tggcaccaga ggtggttaca cggaagcctt atggccctaa agtcgacata
10  1321 tgggtctctgg gtatcatggc tattgagatg gtagaaggag agcctccata cctcaatgaa
      1381 aatcccttga gggccttgta cctaatagca actaatggaa cccagaact tcagaatcca
      1441 gagaaacttt ccccaatatt tcgggatttc ttaaactgat gtttggaat ggatgtggaa
      1501 aaaaggggtt cagccaaaga attattacag catcctttcc tgaaactggc caaaccgta
      1561 tctagcttga caccactgat catggcagct aaagaagcaa tgaagagtaa ccgttaacat
15  1621 cactgctgtg ggctcatact cttttttcca ttttctacaa gaagcctttt agtatatgaa
      1681 aatgatgact ctggtggggg ttttaagaaa tggctctgcat aacctgaatg aaagaaggaa
      1741 atgactattc tctgaagaca accaagagaa aattggaaaa gacaaggtat gactttgtta
      1801 tgaacccttg ctttttagggg tccaggaagg gatttgtggg acttgaattc actaggctta
      1861 ggtctttcag gaaacaggct atcaggggca tttatcatgt gtgagattgg attctacttg
20  1921 ggtgatttgg tggatagacc catgaatggc ccctgggggt tttcaatctt ggattggagg
      1981 tgggggtttc agagtgttgc cagctctagc tcctctccc

```

25

DEFINITION Human cyclin-dependent kinase 4 (CDK4) gene,
complete cds.

ACCESSION U37022

VERSION U37022.1 GI:1353415

30 FEATURES Location/Qualifiers

source

1..4233

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="12"

35 /map="12q13"

/clone="24C7"

mRNA

join(85..291,729..965,1123..1258,1376..1543,1701..1810,
2949..2999,3135..3270,3836..4233)

40 /gene="CDK4"

/product="cyclin-dependent kinase 4"

exon

85..291

/gene="CDK4"

gene

85..4233

45 /gene="CDK4"

exon

729..965

/gene="CDK4"

CDS

join(748..965,1123..1258,1376..1543,1701..1810,2949..2999,
3135..3270,3836..3928)

50 /gene="CDK4"

/codon_start=1

/product="cyclin-dependent kinase 4"

/protein_id="AAC50506.1"

55 /db_xref="GI:1353416"

/translation="MATSRYPVAEIGVGAYGTVYKARDPHSGHFVALKSVRVPNGGG

GGGGLP1STVREVALLRRLAEFHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDLRT

60 YLDKAPPPGLPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKCLADFG

LARIYSYQMALTPVVVTLWYRAPEVLLQSTYATPVDMMWSVGCIFAEMFRRKPLFCGNS

EADQLGKIFDLIGLPPEDDWPRDVS LPRGAFFPRGPRPVQSVVPEMEESGAQLLLEML

TFNPHKRISAFRALQHSYLHKDEGNPE"

	BASE COUNT	945 a	1050 c	1101 g	1124 t	13 others	
5	ORIGIN						
	1	ccctcctccc	agtcgaagca	cctcctgtcc	gcccctcagc	gcatgggtgg	cgggtcacgtg
	61	cccagaacgt	ccggcggttcg	ccccgcctcc	ccagtttccg	cgcgcctctt	tggcagctgg
	121	tcacatggtg	aggggtggggg	tgagggggcc	tctctagctt	gcggcctgtg	tctatggctg
	181	ggccctctgc	gtccagctgc	tccggaccga	gctcgggtgt	atggggccgt	aggaaccggc
10	241	tccggggccc	cgataacggg	ccgccccac	agcaccccgg	gctggcggtga	ggtaagtga
	301	gtcccttccc	aggaatgaga	accagtgcc	gccccctca	cagctttcca	cgcgttcgtt
	361	tcgcgagctg	gttatggaag	ggtcgctcaa	gggcgggaag	tggggccttt	gtgggtcatgg
	421	gaaagtataa	ttttagggac	tgaggtgtag	gatcttcgat	gcaaggcatg	tgtcatgtgt
	481	gatctttgtg	cggggcgcga	ttgtcccaa	ggaaaaagcg	ttttctattg	cagggcctca
15	541	cgtggctgga	gggggttgga	ttgagtcatt	gtgttatctc	tggggccggc	cccaaggaaag
	601	actgggagcg	ggggatggga	tgctgggtgt	gttctttgct	cttttttttt	gggagtcctt
	661	ttgttgctgc	aggtcatacc	atcctaactc	tgtaagcgac	ttttgggtgat	aggagtctgt
	721	gattgtaggg	tctcccttga	tctgagaatg	gctacctctc	gatatgagcc	agtggctgaa
	781	attgggtgtcg	gtgcctatgg	gacagtgtac	aaggcccgtg	atccccacag	tggccacttt
20	841	gtggccctca	agagtgtgag	agtccccaat	ggaggaggag	gtggaggagg	ccttcccatc
	901	agcacagttc	gtgaggtggc	tttactgagg	cgactggagg	cttttgagca	tcccaatggt
	961	gtccgggtgag	aagggtgggtg	agggttgggc	gtggggagta	aagggaaaag	acagcctata
	1021	ggtgggggtgt	gatgatctgt	agagaagtgg	ggaccctgag	gaaataatga	gaggccatgt
	1081	tggtttaaag	gggattgaaa	agtgagcatt	tactctgggtc	aggctgatgg	acgtctgtgc
25	1141	cacatcccga	actgaccggg	agatcaaggt	aaccctgggtg	tttgagcatg	tagaccagga
	1201	cctaaggaca	tatctggaca	aggcaccctc	accaggcttg	ccagccgaaa	cgatcaaggt
	1261	gagtgggggt	ggtaggcatt	gagaggtgga	ttgggacctt	tgtagttagaa	ccttctggga
	1321	tttcagggtat	ggtgcctagt	ttccagtgc	tctgtacctc	cccctttgaa	actaggatct
	1381	gatgcgccag	tttctaagag	gcctagattt	ccttcatgcc	aattgcatcg	ttcaccgaga
30	1441	tctgaagcca	gagaacattc	tggtgacaag	tggtggaaca	gtcaagctgg	ctgactttgg
	1501	cctggccaga	atctacagct	accagatggc	acttacaccc	gtgggtcagta	gaaagatggt
	1561	acaaaaatgg	gttctgggtg	ggaataggag	agtgtattgc	cgtagcaatt	gagaagtcac
	1621	tgcttctcatg	tggttcagtc	agcaagtgtg	gtttcatggt	aaccctaggg	gtccccatcc
	1681	attcttcccta	ttcccttttag	gttggttacac	tctggtaccg	agctcccgaa	gttcttctgc
35	1741	agtcacacata	tgcaacacct	gtggacatgt	ggagtgttgg	ctgtatcttt	gcagagatgt
	1801	ttcgtcgaaa	gtatgggacc	cacataccct	ggactacctt	gaattcccca	aatcgcttgt
	1861	tcataaaacca	catccatacc	ttgcccattc	tttttttttg	agaccagggc	ttgctgtggt
	1921	gcccaggctg	gattgcaatg	gcatagtcac	agctcactgc	agcttcaacc	tcctgggctc
	1981	aagtgcacct	cccatctcag	cttcccaact	agctgacact	acaggcacgc	acctccatgc
40	2041	ttggctagtt	tgtaaatatt	tttatagaga	tggggtctca	gtatattgcc	caggctgggtc
	2101	ttgaactctt	gcactcaagc	aatcctccca	cccctacctc	ccaaagtagc	ataagctact
	2161	gcatctggcc	ccattctttt	acttgcgtac	tactaacttg	cccatagcag	aaagctctga
	2221	aatgttctgg	aattaggaac	ttcatatccc	tttattctct	ttatttttta	tttatttatt
	2281	tattttattta	tttatttatt	gagataaggt	ttcactctgn	nacccaggct	ggagtncaat
45	2341	ggcccaatta	nagctcactg	tancctctac	ctcctgggct	aaagmaatcc	tcccatctca
	2401	gccccttgag	tanctgagac	taaagggtgca	cgccaccatg	actggctttt	ttttttttta
	2461	gatggagtct	tgctctgtcg	ccaggctgga	gtgcagtagt	gcgatctctg	ctcactgcaa
	2521	cctccacctc	ccagattcaa	gcaattctct	tgactcagcc	tcccaagtag	ctgggaccac
	2581	aggtgcacgc	caccatgctc	agctaatttt	tgtactttta	gtaatgacag	gtttcaccat
50	2641	gttggccagg	atggtctcga	tctcttgacc	tcatgatcca	cccacatcag	actcccaaag
	2701	tgctaggatt	acaggcgtga	gcnnnngcac	ctggcatttc	ttttttttta	aaaaaagaga
	2761	caaggctctg	cttgcccagg	ctgatctaga	actcctgggc	tcaagcagtc	ctctcacctc
	2821	agcatcccaa	agtgtctgga	ttgttggcct	ttattcccta	tacttccctat	tttgagccac
	2881	taagcagtaa	ccattcaact	aagatatctt	tgaaaatgac	tgctacctta	tatcccttct
55	2941	caccttaggc	ctctcttctg	tggaaaactct	gaagccgacc	agttgggcaa	aatctttgag
	3001	taagtgaaca	acatgggaga	aaaagatgtt	ctattctgag	tcctctttct	gctgaaccca
	3061	ggatggcaac	tggtctctgc	atggggatgg	gaactggagg	accctcctga	ccagagttct
	3121	cctgtccccc	acagcctgat	tgggtgcct	ccagaggatg	actggcctcg	agatgtatcc
	3181	ctgccccgtg	gagcctttcc	ccccagaggg	ccccgcccag	tgcatcggt	ggtacctgag
60	3241	atggaggagt	cgggagcaca	gctgctgctg	gtaactggag	atggctgtgg	gcacagggaa
	3301	agaaatagag	actggggaaa	gaaatagagc	agtatgcagg	gccctggcca	ctgtggttaa
	3361	tgaactctgg	ttggtagatg	gtctgtagtt	tttattacag	ctgcaaatag	ccaccacag
	3421	agaaggatat	agaagagaac	ccatcctggc	tgggcacggg	ggctcacggc	gttaatccca
	3481	gcactttggg	aggccaaggt	gggcgtatca	cctgaggtca	ggagttcgag	accagcctgg

12/17

```
3541 ccaacatggt gaaacctcgt ctctactaaa agtacaaaaa taagccgggg gtggtggcac
3601 acgcctgttaa tctcagctac ttgggaggct gagataggag aatcacttca actcaggagg
3661 cggagggttgc agtgagctga gttcatacca ttggcactcc agcctgggtg atagagcgag
3721 actccgtctn caaaaaaaaa aaaaaagaaa aaagaagaaa gctcatocca ggtattgttg
5 3781 tgggtggcag aagctgtttt cttcatgggt ttctgacctt tgcctctccc ctcaggaaat
3841 gctgactttt aaccacaca agcgaatctc tgcctttcga gctctgcagc actcttatct
3901 acataaggat gaaggtaatc cggagtggagc aatggagtgg ctgccatgga aggaagaaaa
3961 gctgccattt cctttctgga cactgagagg gcaatctttg cctttatctc tgaggctatg
10 4021 gagggtcctc ctccatcttt ctacagagat tactttgctg ccttaatgac attcccctcc
4081 cacctctcct tttgaggctt ctccttctcc ttcccatttc tctacactaa ggggtatgtt
4141 cctctttgtc cctttcccta cctttatatt tggggtcctt ttttatacag gaaaaacaaa
4201 accaaaagaa awaatggccc tttttttttt ttt
```

15

DEFINITION Human MEK5 mRNA, complete cds.

ACCESSION U25265

VERSION U25265.1 GI:1255719

20 FEATURES

Location/Qualifiers

source

1..2083

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="3-2"

25

/tissue_type="brain"

/clone_lib="cDNA Lambda ZAP (Invitrogen)"

/dev_stage="fetal"

CDS

297..1613

/codon_start=1

30

/product="MEK5"

/protein_id="AAA96146.1"

/db_xref="GI:1255720"

/translation="MLWLALGPFPMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDV

35

LDVIGQVLPEATTTAFEYEDGDGRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPL

QIFPRACKPPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQ

40

MNEQDIRYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDTLELQKQIMSELEILYK

CDSSYIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPHEVLGRIAVAVVKGLTYLWS

LKILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGEQYQ

45

IHSDVWSLGISFMEIQKNQGSMLPLQLLQCIVDEDSPLVLPVGEFSEPFVHFITQCMRK

QPKERPAPPEELMGHPFVQFNDGNAVVSMWVCRALERRSQQGP

BASE COUNT

518 a

532 c

512 g

521 t

ORIGIN

50

1 agcgttcgct caactccaga accttccgac ctccgctagt tcttgcgggc ctttgcgccg

61 ttcccgggtgc accctccccg ggagacacct cagacccccg acagcctggg caggctcggg

121 gcctgcgggt gcgttcctga tcacctctcc cctcttccct cccctctatc ctccattccc

181 ttgttttcac cctctgtctc ctgcccgta ctccccttgt cacctcttgg agccccctcc

55

241 taaccagcgg ccagtgggtt tccataccc caggatgtga gcctctttaa cctgtaatgc

301 tgtgtctagc ccttggcccc tttcctgcca ttgagaacca ggtgctggtg attcgcatca

361 agatcccaaa tagtggcgcg gtggactgga cagtgcactc cgggcgcgag ttactcttca

421 gggatgtgct ggatgtgata ggccagggtc tgcctgaagc aacaactaca gcatttgaat

481 atgaagatga agatggtgat cgaattacag tgagaagtga tgaggaaatg aaggcaatgc

60

541 tgtcatatta ttattccaca gtaatggaac agcaagtaaa tggacagtta atagagcctc

601 tgcagatatt tccaagagcc tgcaagcctc ctggggaacg gaacatacat ggcctgaagg

661 tgaatactcg ggccggaccc tctcaacaca gcagcccagc agtctcagat tcacttccaa

721 gcaatagctt aaagaagtct tctgctgaac tgaaaaaaat actagccaat ggccagatga

781 atgaacaaga catacgatat cgggacactc ttggtcatgg caacggaggc acagtctaca

841 aagcatatca tgtcccagat gggaaaatat tagctgtaaa ggtcatacta ctagatatta

```

    901 cactggaact tcagaagcaa attatgtctg aattggaaat tctttataag tgcgattcat
    961 catatatcat tggattttat ggagcatttt ttgtagaaaa caggatttca atatgtacag
1021 aattcatgga tgggggatct ttggatgtat ataggaaaat gccagaacat gtccttgga
1081 gaattgcagt agcagttggt aaaggcctta cttatttgtg gagtttaaag attttacata
  5 1141 gagacgtgaa gccctccaat atgctagtaa acacaagagg acagggttaag ctgtgtgatt
    1201 ttggagttag cactcagctg gtgaattcta tagccaagac gtatgttggg acaaatgctt
    1261 atatggcgcc tgaaaggatt tcagggggagc agtatggaat tcattctgat gtctggagct
    1321 taggaatctc ttttatggag attcagaaaa accagggatc tttaatgcct ctccagcttc
    1381 tgcagtgcac tgttgatgag gattcgcccg tccttcagct tggagagttc tcggagccat
10 1441 ttgtacattt catcactcag tgtatgcgaa aacagccaaa agaaaggcca gcacctgaag
    1501 aattgatggg ccacccgttc atcgtgcagt tcaatgatgg aaatgccgcc gtggtgtcca
    1561 tgtgggtgtg ccgggcgctg gaggagaggc ggagccagca gggggccccc tgaggctgcc
    1621 gcagggcact gaaagcccag gaccagtaac caaggagAAC aaccacccc tcgcccttct
    1681 ccgtatgctg cctgcgccag aagagctttg ctgggcccctg gcttcctctgc cctgccttc
15 1741 acctctgtca gcaggtggcc ttgcctgggg agcccatgt gtggcccacc ccaccaggcc
    1801 atccccatac cttctggttt gaaggcgctg acactggcag agaggtaaag ggtggggcat
    1861 tgagaatgga ggctcccagg gtccctgccc acttctgttt tcctaagtgt tttctctata
    1921 aagggtcagg cccgtcagca tctactgatg gaataaaagt attaatgctt tgtgacagcc
    1981 tctgcctgaa aactggacag aaggaccagc aggtgttctt tcattttctc tcttacctcc
20 2041 aatctttccc ctttcaagct acaggtaaag gctctaccac cat
```

25 DEFINITION Homo sapiens a disintegrin and metalloproteinase domain 22

(ADAM22), transcript variant 3, mRNA.

ACCESSION NM_016351

VERSION NM_016351.2 GI:11497041

30 FEATURES Location/Qualifiers

source

1..3314

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="7"

/map="7q21"

35

gene

1..3314

/gene="ADAM22"

/note="MDC2"

/db_xref="LocusID:53616"

40

CDS

/db_xref="MIM:603709"

47..2659

/gene="ADAM22"

/note="isoform 3 is encoded by variant 3"

/codon_start=1

45

/db_xref="LocusID:53616"

/db_xref="MIM:603709"

/product="a disintegrin and metalloproteinase domain

22,

isoform 3 preproprotein"

50

/protein_id="NP_057435.1"

/db_xref="GI:7706613"

/translation="MQAAVAVSVPFLLLCVLGTCPPARCGQAGDASLMELEKRKENRF

55 VERQSIVPLRLIYRSGGEDES RHDALDTRVRGDLGGRQLTHVDQASFQVDAFGTSFIL

DVVLNHDLLSSEYIERHIEHGGKTVEVKGGEHCYYQGHIRGNPDSFVALSTCHGLHGM

FYDGNHTYLIEPEENDTTQEDFHFHSVYKSRLFEFSLDDLPSEFQQVNITPSKFILKP

60

RPKRSKRQLRRYPRNVEETKYIELMIVNDHLMFKKRLSVVHTNTYAKSVVNMADLI

YKDQLKTRIVLVAMETWATDNKFAISENPLITLREFMKYRRDFIKEKSDAVHLFSGSQ

FESSRSGAAYIGGICSLKGGGVNEFGKTDLMVTLAQSLAHNIGIISDKRKLASGEC

KCEDTWSGCIMGDTGYLPPKFTQCNIIEYHDFLNSGGGACLFNKPSKLLDPPECNGN

FIETGEECDGCTPAECVLEGAECCKKCTLTQDSQCSDDLCKKCKFQPMGTVCRAVN

DCDIRETCSGNSSQCAPNIHKMDGYSCDGVQIGCFGGRCKTRDRQCKYIWGQKVTASD

KYCYEKLNIEGTEKGNCGKDKDTWIQCNRDVLGCGYLLCTNIGNIPRLGELDGEITST

LVVQQGRTLNCSSGGHVKLEEDVDLGYVEDGTPCGPQMMCLEHRCLEPVASFNFSTCLSS

KEGTICSGNGVCSNELKVCNHRHWIGSDCNTYFPHNDDAKTGITLSGNGVAGTNIIIG

IIAGTILVLALILGITAWGYKNYREQRSNGLSHSWSERIPDTKHISDICENGRPRSNS

WQGNLGGNKKKIRGKRFRPRSNSTETLSPAKSPSSSTGSIASSRKYPYPMPLPDEDK

KVNQRSARLWETSI"

BASE COUNT 1000 a 641 c 779 g 891 t 3 others

ORIGIN

1 catgaggagc tgagcgtctc gggcgaggcg ggctgacggc agcaccatgc aggcggcagc

61 ggctgtgtcc gtgcccttct tgtctgtctg tgtcctgggg acctgccctc cgccgcgctg

121 cggccaggca ggagacgcct cattgatgga gctagagaag aggaaggaaa accgcttcgt

181 ggagcgccag agcatcgtgc cactgcgcct catctaccgc tcggggcgcg aagacgaaaag

241 tcggcacgac gcgctcgaca cgcgggtgcg gggcgacctc ggtggccggc agttgactca

301 tgttgaccaa gcaagcttcc aggttgatgc ctttggaacg tcattcattc tcgatgtcgt

361 gctaaatcat gatttgctgt cctctgaata catagagaga cacattgaac atggaggcaa

421 gactgtggaa gttaaaggag gagagcactg ttactaccag ggccatatcc gaggaaaccc

481 tgactcattt gtgcattgtt caacatgccca cggacttcat gggatgttct atgacgggaa

541 ccacacatat ctcattgagc cagaagaaaa tgacactact caagaggatt tccattttca

601 ttcagtttac aaatccagac tgtttgaatt ttccttggtg gatcttccat ctgaatttca

661 gcaagtaaac attactccat caaaatttat tttgaagcca agaccaaata ggagtaaacg

721 gcagcttcgt cgatatcctc gtaatgtaga agaagaaacc aaatacattg aactgatgat

781 tgtgaatgat cacccttatgt ttaaaaaaca tcggctttcc gttgtacata ccaataccta

841 tgcgaaatct gtggtgaaca tggcagattt aatatataaa gaccaactta agaccaggat

901 agtattgggt gctatggaaa cctgggagac tgacaacaag tttgccatat ctgaaaatcc

961 attgatcacc ctacgtgagt ttatgaaata caggagggat tttatcaaag agaaaagtga

1021 tgcagttcac cttttttcgg gaagtcaatt tgagagtagc cggagcgggg cagcttatat

1081 tggtgggatt tgctcggtgc tgaaggagg aggcgtgaat gaatttggga aaactgattt

1141 aatggctggt acacttgccc agtcattagc ccataatatt ggtattatct cagacaaaag

1201 aaagttagca agtgggtgaat gtaaatgcga ggacacgtgg tcggggtgca taatgggaga

1261 cactggctat tatcttccta aaaagttcac ccagtgtaat attgaagagt atcatgactt

1321 cctgaatagt ggaggtgggt cctgcctttt caacaaacct tctaagcttc ttgatcctcc

1381 tgagtgtggc aatggcttca ttgaaactgg agaggagtgt gattgtggaa ccccgccga

1441 atgtgtcctt gaaggagcag agtgtgtgaa gaaatgcacc ttgactcaag actctcaatg

1501 cagtgcagggt ctttgctgta aaaagtgcga gtttcagcct atgggcactg tgtgccgaga

1561 agcagtaaat gattgtgata ttcgtgaaac gtgctcagga aattcaagcc agtgtgcccc

1621 taatattcat aaaatggatg gatattcatg tgatgggtgt caggggaattt gctttggagg

1681 aagatgcaaa accagagata gacaatgcaa atacatttgg gggcaaaaag tgacagcatc

1741 agacaaatat tgctatgaga aactgaatat tgaaggagc gagagggta actgtgggaa

1801 agacaaagac acatggatac agtgcaacaa acgggatgtg ctttgtggtt accttttgtg

1861 taccaatatt ggcaatatcc caaggcttgg agaactcgat ggtgaaatca catctacttt

1921 agttgtgcag caaggaagaa cattaaactg cagtgggtgg catgttaagc ttgaagaaga

1981 tgtagatctt ggctatgtgg aagatgggac accttgtggt ccccaaatga tgtgcttaga

2041 acacaggtgt cttcctgtgg cttctttcaa ctttagtact tgcttgagca gtaaagaagg

2101 cactatttgc tcaggaaatg gagtttgacg taatgagctg aagtgtgtgt gtaacagaca

2161 ctggataggt tctgattgca acacttactt ccctcacaat gatgatgcga agactgggat

2221 cactctgtct ggcaatgggt ttgctggcac caatatcata ataggcataa ttgctggcac

2281 catttttagtg ctggccctca tattaggaat aactgcgtgg ggttataaaa actatcgaga

2341 acagaggtca aatgggctct ctcattcttg gagtgaaggg attccagaca caaaacatat

2401 ttcagacatc tgtgaaaatg ggcgacctcg aagtaactct tggcaaggta acctggggag

2461 caacaaaaag aaaatcagag gcaaaaagatt tagacctcgg tctaattcaa ctgagacttt

2521 atctcctgce aagtctcctt cttcatcaac tgggtctatt gcctccagca gaaaataccc

```
2581 ttacccaatg cctccacttc ctgatgagga caagaaagtg aaccgacaaa gtgccaggct
2641 atggggagaca tccattttaag atcaactggt tacatgtgat acatcgaaaa ctgtttactt
2701 caacttttat agaaaccag gctcatggaa tcatcgaaa tctatctgct cttcagacaa
2761 tacgaagacc ctctgagatg ctacagagga gaggaagcgg agtttcacat ctggttacca
5 2821 ttttcttttt gtcatgtggt taggatttaa ctaaccatga aaagaactac tgaaatatta
2881 cactataaca tggaacaata aaggtactgg tatgttaatg gataatccgc atgacagata
2941 atatgtagaa atattcataa agttaactca catgacccaa atgtagcaag tttcctaagg
3001 tacaatagtg gattcagaac ttgacgttct gaggcacatc ctcactgtaa acagtaatgc
3061 tatatgcatg aagcttctgt ttattgtttt ccatatttaa ggaaacaaca tcccataata
10 3121 gaaatgagca tgcagggcta aggcataatag gatttttctg caggacttta aagctttgaa
3181 aggccaatat cccataggct aactttaaac atgtattttt atttttgntt tgntttttac
3241 ttttcatatt tatattagca tacaaggaca attgnatata tgtaacattt ttaaaatttt
3301 aaaaaaaaaa aaaa
```

15

```
DEFINITION Homo sapiens a disintegrin and metalloproteinase domain 17
(tumor necrosis factor, alpha, converting enzyme) (ADAM17),
20 transcript
variant 1, mRNA.
ACCESSION NM_003183
VERSION NM_003183.3 GI:11497003
25 FEATURES
Location/Qualifiers
source 1..3523
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="2"
30 /map="2p25"
gene 1..3523
/gene="ADAM17"
/note="TACE; CSVP; CD156b"
/db_xref="LocusID:6868"
35 /db_xref="MIM:603639"
CDS 165..2639
/gene="ADAM17"
/note="isoform 1 is encoded by transcript variant 1;
TNF-alpha converting enzyme; snake venom-like
40 protease"
/codon_start=1
/db_xref="LocusID:6868"
/db_xref="MIM:603639"
/product="a disintegrin and metalloproteinase domain
45 17,
isoform 1 preproprotein"
/protein_id="NP_003174.2"
/db_xref="GI:11497004"
50 /translation="MRQSLFLTSVVPFVLAPRPDDPGFGPHQRLEKLDLLSDYDI
LSLSNIQQHSVRKRDLOTSTHVETLLTFSALKRHFKLYLTSSTERFSQNFKVVVVVDGK
NESEYTAKWQDFFTGHVVGEPDSRVLAHIRDDDDVIIRINTDGAEYNIEPLWRFVNDTK
55 DKRMLVYKSEDIKNVSRLQSPKVCGYLKVDNEELLPKGLVDREPPEELVHRVKRRADP
DPMKNTCKLLVADHRFYRYMGRGEESTTTNYLIELIDRVDDIYRNTSWDNAGFKGYG
60 IQIEQIRILKSPQEVKPGKEKHYNMAKSYPNEEKDAWDVKMLLEQFSFDIAEEASKVCL
AHLFTYQDFDMGTLGLAYVGSPRANSHGGVC PKAYYSPVGKKNIYLN SGLTSTKNYKG
TILTKEADLVTTHELGHNFGAEHDPDGLAEAPNEDQGGKYVMYPIAVSGDHENNKMF
```

SNCSKQSIYKTIESKAQECFQERSNKVCGNSRVDEGEECDPGIMYLNNDTCCNSDCTL

KEGVQCSDRNSPCKKNCQFETAQKKCQEAINATCKGVSYCTGNSSECPPPGNAENDTV

5

CLDLGKCKDGKCIPIFCEREQQLSCACNETDNSCKVCCRDLSGRVCVPYVDAEQKNLFL

RKGKPCTVGFCDMNGKCEKRVQDVIERFWDFIDQLSINTFGKFLADNIVGSVLVFSLI

10

FWIPFSILVHCVDKLDKQYESLSLFHPSNVEMLSMDSASVRIKPPAPQTPGRLO

PAPVIPSAPAAPKLDHQRMDTIQEDPSTDHMDDEDFEKPDPFNSSTAAKSFEDLTDH

PVARSEKAASFKLQRQNRVNSKETEC"

BASE COUNT 1025 a 685 c 845 g 968 t

15

ORIGIN

1	tcgagcctgg	cggtagaatc	ttcccagtag	gcggcgcggg	agggaaaaga	ggattgaggg
61	gctaggccgg	gcggtatccg	tcctccccc	atgtgagcag	ttttccgaaa	ccccgtcagg
121	cgaaggctgc	ccagagaggt	ggagtcggtg	gcggggccgg	gaacatgagg	cagtctctcc
181	tattcctgac	cagcgtgggt	cctttcgtgc	tggcgccgg	acctccggat	gacccgggct
241	tcggccccc	ccagagactc	gagaagcttg	attccttgct	ctcagactac	gatattctct
301	ctttatctaa	tatccagcag	cattcggtgaa	gaaaagaga	tctacagact	tcaacacatg
361	tagaaacact	actaactttt	tcagctttga	aaaggcattt	taaattatac	ctgacatcaa
421	gtactgaacg	tttttcacaa	aatttcaagg	tcgtgggtgg	ggatggtaaa	aacgaaagcg
481	agtacactgc	aaaatggcag	gacttcttca	ctggacacgt	ggttgggtgag	cctgactcta
541	gggttctagc	ccacataaga	gatgatgatg	ttataatcag	aatcaacaca	gatggggccg
601	aatataacat	agagccactt	tggagatttg	ttaatgatac	caaagacaaa	agaatgttag
661	tttataaatc	tgaagatatc	aagaatgttt	cacgtttgca	gtctccaaaa	gtgtgtgggt
721	atttaaaagt	ggataatgaa	gagttgctcc	caaaagggtt	agtagacaga	gaaccacctg
781	aagagcttgt	tcacgagtg	aaaagaagag	ctgaccacga	tcccatgaag	aacacgtgta
841	aattattggg	ggtagcagat	catcgcttct	acagatacat	gggcagaggg	gaagagagta
901	caactacaaa	ttacttaata	gagctaattg	acagagttga	tgacatctat	cggaaacactt
961	catgggataa	tgcaggtttt	aaaggctatg	gaatacacag	agagcagatt	cgcatttctca
1021	agtctccaca	agaggtaaaa	cctggtgaaa	agcactacaa	catggcaaaa	catgtaccac
1081	atgtacaaaa	ggatgctttg	gatgtgaa	tggtgctaga	gcaatttagc	tttgatatag
1141	ctgaggaagc	atctaaagtt	tgcttggtgc	accttttcac	ataccaagat	tttgatatgg
1201	gaactcttgg	attagcttat	gttggtcttc	ccagagcaaa	cagccatgga	gggtgttggtc
1261	caaaggctta	ttatagccca	gttggtgaa	aaaatatcta	tttgaatagt	gggttgacga
1321	gcacaaagaa	ttatggtaaa	accatcctta	caaaggaagc	tgacctggtt	acaactcatg
1381	aattgggaca	taattttgga	gcagaacatc	atccggatgg	tctagcagaa	tgtgccccga
1441	ataggagcca	gggagggaaa	tatgctcatg	atcccatagc	tgtgagtggt	gatcacgaga
1501	acaataagat	gttttcaaac	tgcagtaaac	aatcaatcta	taagaccatt	gaaagtaagg
1561	cccaggagtg	ttttcaagaa	cgcagcaata	aagtttgtgg	gaactcgagg	gtggatgaag
1621	gagaagagtg	tgatcctggc	atcatgtatc	tgaacaacga	cacctgctgc	aacagcgact
1681	gcacgttgaa	ggaaggtgtc	cagtgcagtg	acaggaacag	tccttgctgt	aaaaactgtc
1741	agttttgagc	tgcccagaag	aagtgcagg	aggcgattaa	tgctacttgc	aaaggcgtgt
1801	ccttctgcac	aggtaatgac	gtgagtgcc	cgcctccagg	aaatgctgaa	aatgacactg
1861	tttgcttgga	tcttggtcag	tgtaaggatg	ggaaatgcat	ccctttctgc	gagaggggaa
1921	agcagctgga	gtcctgtgca	tgtaaatgaa	ctgacaactc	ctgcaagggt	tgctgcaggg
1981	acctttctgg	ccgctgtgtg	ccctatgtcg	atgctgaaca	aaagaactta	tttttgagga
2041	aaggaaagcc	ctgtacagta	ggattttgtg	acatgaatgg	caaatgtgag	aaacgagtac
2101	aggatgtaat	tgaacgattt	tgggatttca	ttgaccagct	gagcatcaat	acttttggaa
2161	agtttttagc	agacaacatc	gttgggtctg	tcctgggttt	ctccttgata	ttttggattc
2221	ctttcagcat	tcttgtccat	tgtgtggata	agaaattgga	ttaacagtat	gaatctctgt
2281	ctctgtttca	ccccagtaac	gtcgaaatgc	tgagcagcat	ggattctgca	tgggttcgca
2341	ttatcaaacc	ctttcctgcy	ccccagactc	caggccgcct	gcagcctgcc	cctgtgatcc
2401	cttcggcgcc	agcagctcca	aaactggacc	accagagaat	ggacaccatc	caggaagacc
2461	ccagcacaga	ctcccatatg	gacgaggtat	ggtttgagaa	ggacccttcc	ccaaatagca
2521	gcacagctgc	caagtcattt	gaggacttca	cggaccatcc	ggtcgccaga	agtgaagagg
2581	ctgcctcctt	taaactgcag	cgtcagaatc	gtgttaacag	caaagaaaca	gagtgtcaat
2641	ttagttctca	gctcttctga	cttaagtgtg	caaaatatatt	ttatagattt	gacctacaaa
2701	tcaatcacag	cttgatattt	gtgaagactg	ggaagtgact	tagcagatgc	tggtcatgtg
2761	tttgaacttc	ctgcaggtaa	acagttcttg	tgtgggttgg	cccttctcct	tttgaagagg
2821	taaggtgaaa	gtgaatctac	ttattttgag	gctttcagg	tttagttttt	aaaatatctt
2881	ttgacgtgtg	gtgcaaaaag	agaaaataga	gctggattgg	gttatgaata	tttacgtttt

2941 tgtaaattaa tctttttatat tgataacagc actgactagg gaaatgatca gttttttttt
3001 atacactgta atgaaccgct gaatatgaag catttgcat ttatttgtga gaaaagtggga
3061 atagtttttt tttttttttt ttttttttgc cttcaactaa aaacaaagga gataaattta
3121 gtatacattg tatctaaatt gtgggtctat ttctagttag taccagagt ttttatgtag
5 3181 cagggaaaat atatatctaa atttagaaat catttgggtt aatatggctc ttcataattc
3241 taagactaat gctcagaacc taaccactac cttacagtga gggctataca tggtagccag
3301 ttgaatttat ggaatctacc aactgtttag ggcctgatt tgctgggcag tttttctgta
3361 ttttataagt atcttcatgt atccctgtta ctgataggga tacatgtctt agaaaattca
3421 ctattggctg ggagtgggtg ctcatgcctg taatcccagc acttggagag gctgaggttg
10 3481 cgccactaca ctccagcctg ggtgacagag tgagatctgc ctc

Accession number: NM_007026

Definition: DUSP14, MKP-L

15 GTGGCCGCGCAGGAGGACGGAGCCCTAACCGCAACCCGCGCCGCGCCGCGCGATTGATTTGTATCCAC
TGTCACCAGCACTGCTCACTTAGGACTTTCTGGATCCAGACCCAGGCAGCGCACACTGGACTCTTGAGGA
AGAAGGAGACTCTAATTTTGGATTCTTGGTGGAGGAAAAATAAACACTCTGGTCTTGCCGCCAACGATG
CAAGTGTGACTGCTGGCGTCTTCATGAGCTCCAGAGGTCACAGCACGCTACCAAGGACTCTCATGGCCCC
TCGGATGATTTCCGAGGGAGACATAGGAGGCATTGCTCAAATCACCTCCTCTCTATTCTGGGCAGAGGC
20 AGTGTGGCCTCCAATCGGCACCTCCTCCAGGCTCGTGGCATCACCTGCATTGTTAATGCTACCATTGAGA
TCCCTAATTTCAACTGGCCCCAATTTGAGTATGTTAAAGTGCCTCTGGCTGACATGCCGCATGCCCCCAT
TGGACTGTACTTTGACACCGTGGCTGACAAGATCCACAGTGTGAGCAGGAAGCACGGGGCCACCTTGGTG
CACTGTGCTGCAGGGGTGAGCCGCTCAGCCACGCTGTGTATCGCGTACCTGATGAAATTCACAACGTGT
GCCTGCTGGAGGCATACAACTGGGTGAAAGCCCGGCGACCTGTCTATCAGGCCAACGTAGGCTTCTGGAG
25 GCAACTGATAGACTACGAGCGCCAGCTCTTTGGGAAGTCGACAGTTAAAATGGTACAGACACCTTATGGC
ATAGTTCCCGACGTCTATGAGAAGGAGTCCCGACACCTGATGCCCTTACTGGGGGATTTAGTGCCACTGAA
GCCTGCGTCTAGCAGCCCGAGCGGGGCCGCATCTGCTCCCGCCGCTCTGCTCCCTCTCCACTCTCTCTC
AAATGGCTGACTTCTGGTTCTCCCTCAAGTGTTTTTTACACTGGGTGTTCAAATTTATTTTAAGAGATAG
GGAGGGAGGGGACATAAAGGGAATGCATACATTGCTAGTCACATTTTTTAAATTAACATTTTGGAATAGT
30 GTTTATGGAAATCTTTAGCTTTTAAATCATTTTTACCAATTTGAACAGTTTAAATAAACTGGTTCTGCTCTC
TTCTGAATCTCATGCCTTTGGCACCTTGGTAGGTGCAGGAGGAGCTCAGTGCAAAAATCACTTTGGGGCC
TCATTAACCCTTTAGAGACAAGCTTTGCCCCAGGCTGCGGACCAGACAGATGCTTAGGGAAGGTTGATAC
CAGCTTCAGTCTCTACTGGATTAGCCCTACTCTTCCCTTCCCTCCATTATTTAGTGACTCTGTAAGTA
AGTTAAATACACCCTTATTATTTAGCTGTTAAGTAACTATAATGAAATCTGCTGCAAAATCTCTCTTGA
35 ATCCATGTGCCAGGATTATATTAGCATTATTTTAAATAAATCTATATGCTTAAAAAAAAAAAAAAAAAA
A

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number
WO 2003/054228 A3

(51) International Patent Classification⁷: C12Q 1/42, 1/48,
1/37, 1/68, C07K 16/00, A61K 39/42

(74) Agents: GINZEL, Christian et al.; c/o Zimmermann &
Partner, Postfach 330 920, 80069 Munich (DE).

(21) International Application Number:
PCT/EP2002/014578

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(22) International Filing Date:
19 December 2002 (19.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/341,757 21 December 2001 (21.12.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): AXXIMA
PHARMACEUTICALS AG [DE/DE]; Max-Leb-
sche-Platz 32, 81377 München (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SALASSIDIS, Kon-
stadinos [GR/DE]; Hauptstrasse 14c, 85386 Eching (DE).
SCHUBART, Daniel [DE/DE]; Avenue Charles de Gaulle
1c, 13469 Berlin (DE). GUTBROD, Heidrun [DE/DE];
Weberhofstrasse 8, 82166 Graefelfing (DE). MUELLER,
Stefan [DE/DE]; Thalkirchnerstrasse 184, 81371 Munich
(DE). KRAETZER, Friedrich [DE/DE]; Geisenbrunner-
strasse 51, 81475 Munich (DE). OBERT, Sabine [DE/DE];
Bellinzonastrasse 17, 81475 Munich (DE).

Published:

— with international search report

(88) Date of publication of the international search report:
15 January 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 2003/054228 A3

(54) Title: HUMAN CELLULAR ENZYMES AS TARGETS AGAINST HEPATITIS C VIRUS INFECTIONS

(57) Abstract: The present invention relates to human cellular protein kinases, metalloproteases and one phosphatase: beta-adren-
ergic receptor kinase 1 (NM 001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated
protein kinase 1 (U08316), Discoidin domain receptor family, member 1 (NM 013994), Protein Kinase C, mu (X75756), Protein
Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein
kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM 007026), ADAM22 (NM 016351), and
ADAM17 (U92649) as potential targets for medical intervention against Hepatitis C virus (HCV) infections. The present invention
relates also to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections, a
method for detecting Hepatitis C virus infections in an individual or in cells. Mono- or polyclonal antibodies are disclosed effective
for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis
C virus production and/or replication wherein said antibodies may be used. Finally the present invention relates to a solid support
useful for detecting Hepatitis C virus infections or for screening compounds useful for prophylaxis and/or treatment of HCV infec-
tions.

INTERNATIONAL SEARCH REPORT

Additional Application No
PCT/EP 02/14578

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/42 C12Q1/48 C12Q1/37 C12Q1/68 C07K16/00
A61K39/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, EMBASE, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRANCH ANDREA D ET AL: "The coming impact of gene expression profiling on the diagnosis and treatment of HCV-associated liver disease." ANTIVIRAL RESEARCH, vol. 52, no. 2, November 2001 (2001-11), pages 173-179, XP002249604 ISSN: 0166-3542 the whole document	1-14
X	BIGGER CATHERINE B ET AL: "DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection." JOURNAL OF VIROLOGY, vol. 75, no. 15, August 2001 (2001-08), pages 7059-7066, XP002249605 ISSN: 0022-538X the whole document	1-14

-/--

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

30 July 2003

Date of mailing of the international search report

21/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Niemann, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/14578

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YAMASHITA TARO ET AL: "Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 282, no. 2, 30 March 2001 (2001-03-30), pages 647-654, XP002249606 ISSN: 0006-291X the whole document</p>	1-14
X	<p>-----</p> <p>HUANG YING ET AL: "A human hepatoma cell line expressing hepatitis C virus nonstructural proteins tightly regulated by tetracycline." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 281, no. 3, 2 March 2001 (2001-03-02), pages 732-740, XP002249607 ISSN: 0006-291X the whole document</p> <p>-----</p>	1-14

INTERNATIONAL SEARCH REPORT

...ternational application No.
PCT/EP 02/14578

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 2, 3. are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 6-9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition

Continuation of Box I.2

Present claims 6-7, 14 relate to an agent defined by reference to a desirable characteristic or property, namely inhibiting at least aprtially the activity of at least one of the enzymes cited in claim 1.

The claims cover all agents having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such agent. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the agent by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibody which binds to at least one of the enzymes cited in claim 1 (see claim 8).

Present claims 10-11 relate to an oligonucleotide defined by reference to a desirable characteristic or property, namely being capable of detecting activity of at least one of the enzymes cited in claim 1.

The claims cover all oligonucleotides having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such oligonucleotide. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the oligonucleotide by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to oligonucleotides encoding one of the enzymes cited in claim 1 (see claim 12).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1 : 1-14 (all partially)

method for detecting compounds useful for the prophylaxis
and/or treatment of Hepatitis C virus infection, the method
comprising contacting a test compound with at least
beta-adrenergic receptor kinase 1
method for detecting Hepatitis C virus infection

Inventions 2-14 : 1-14 (all partially)

method for detecting compounds useful for the prophylaxis
and/or treatment of Hepatitis C virus infection, the method
comprising contacting a test compound with at least one of
the enzymes mentioned in claim 1
method for detecting Hepatitis C virus infection

THIS PAGE LEFT BLANK